

Quantifying effect of statins on low density lipoprotein disease, and stroke: systematic review and meta-analysis

BMJ: British Medical Journal

326, 1423-0

DOI: [10.1136/bmj.326.7404.1423](https://doi.org/10.1136/bmj.326.7404.1423)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Scientific Review and Clinical Applications. JAMA - Journal of the American Medical Association, 2002, 287, 379.	3.8	2
2	Schlaganfallprophylaxe aus der Sicht des Gefäßchirurgen?ein Update. Gefasschirurgie, 2003, 8, S22-S28.	0.7	0
3	Environmental tobacco smoke and ischemic heart disease. Progress in Cardiovascular Diseases, 2003, 46, 31-38.	1.6	144
4	Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Family Practice, 2003, 4, 18.	2.9	133
5	High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis. JAMA - Journal of the American Medical Association, 2003, 290, 2322.	3.8	50
6	Rapid advances. British Dental Journal, 2003, 195, 419-419.	0.3	0
7	Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. European Heart Journal, 2003, 24, 1719-1726.	1.0	105
8	Coronary heart disease prevention: insights from modelling incremental cost effectiveness. BMJ: British Medical Journal, 2003, 327, 1264-0.	2.4	50
9	A strategy to reduce cardiovascular disease by more than 80%. BMJ: British Medical Journal, 2003, 326, 1419-0.	2.4	1,300
10	Clinical Management of Children and Young Adults with Heterozygous Familial Hypercholesterolaemia in the UK. Journal of the Royal Society of Medicine, 2004, 97, 226-229.	1.1	5
11	Novel antihypertensive agents. Expert Opinion on Investigational Drugs, 2004, 13, 987-998.	1.9	1
12	High-Density Lipoprotein as a Key Component in the Prevention of Premature Atherosclerotic Disease in the Insulin Resistance Syndrome. Seminars in Vascular Medicine, 2004, 4, 215-223.	2.1	4
13	Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. Cmaj, 2004, 171, 1189-1192.	0.9	135
14	Longevity in the 21st Century. British Actuarial Journal, 2004, 10, 685-832.	0.2	77
15	Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax, 2004, 59, 777-782.	2.7	277
17	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation, 2004, 110, 227-239.	1.6	5,602
18	Stopping Statins. Circulation, 2004, 110, 2280-2282.	1.6	14
19	Should Angiotensin II Receptor Blockers and Statins Be Combined?. Circulation, 2004, 110, 1013-1020.	1.6	86

#	ARTICLE	IF	CITATIONS
20	Other articles noted: 25 Jul 03 to 7 Nov 03. Evidence-based Nursing, 2004, 7, 1e-1.	0.1	1
21	Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases. <i>Journal of Epidemiology and Community Health</i> , 2004, 58, 1047-1051.	2.0	62
22	Inflammation, Cholesterol Levels, and Risk of Mortality Among Patients Receiving Dialysis. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1833.	3.8	4
23	Drug Treatment of Hyperlipidemia in Women. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2243.	3.8	237
24	The Challenge of Stroke Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 621.	3.8	18
25	Effectiveness of Statin Therapy in Adults With Coronary Heart Disease. <i>Archives of Internal Medicine</i> , 2004, 164, 1427.	4.3	231
26	Paying for statins. <i>BMJ: British Medical Journal</i> , 2004, 328, 400-402.	2.4	6
27	Favorable Outcome of Ischemic Stroke in Patients Pretreated with Statins. <i>Stroke</i> , 2004, 35, 1117-1121.	1.0	190
28	Editorial Comment—Statin, Stroke Outcome, and Stroke Prevention: When Should We Start Treatment?. <i>Stroke</i> , 2004, 35, 1121-1123.	1.0	9
29	Cholesterol Is Associated With Stroke, but Is Not a Risk Factor. <i>Stroke</i> , 2004, 35, 1524-1525.	1.0	18
31	Statins Inhibit Synthesis of an Oxysterol Ligand for the Liver X Receptor in Human Macrophages With Consequences for Cholesterol Flux. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2365-2371.	1.1	137
32	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, e149-61.	1.1	189
33	Statins: potent vascular anti-inflammatory agents. <i>International Journal of Clinical Practice</i> , 2004, 58, 41-48.	0.8	24
34	A review of the efficacy of rosuvastatin in patients with type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2004, 58, 30-40.	0.8	14
35	Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 640-651.	1.1	259
36	Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 310-316.	1.1	7
37	Rationale, design and methods of the CASHMERE study+. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 131-138.	1.0	19
38	Over-the-counter medicines. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 231-234.	1.1	16

#	ARTICLE	IF	CITATIONS
39	Update on statins. Journal of Vascular Nursing, 2004, 22, 49-50.	0.2	1
40	Improved outcomes of carotid endarterectomy: The critical role of vascular surgeons. Seminars in Vascular Surgery, 2004, 17, 214-218.	1.1	9
41	Consumer behavior in the setting of over-the-counter statin availability: Lessons from the Consumer Use Study of OTC Mevacor. American Journal of Cardiology, 2004, 94, 22-29.	0.7	29
42	Update on statins. Intensive and Critical Care Nursing, 2004, 20, 53-55.	1.4	2
43	Strategies in the high-risk cardiac patient undergoing non-cardiac surgery. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2004, 18, 549-563.	1.7	15
46	Role of fibrates in reducing coronary risk: a UK Consensus. Current Medical Research and Opinion, 2004, 20, 241-247.	0.9	53
48	Improved outcomes of carotid endarterectomy: The critical role of vascular surgeons. Seminars in Vascular Surgery, 2004, 17, 214-218.	1.1	13
49	Patients with abdominal aortic aneurysm: Are we missing the opportunity for cardiovascular risk reduction?. Journal of Vascular Surgery, 2004, 40, 691-697.	0.6	48
50	Impact of kidney transplantation on the progression of cardiovascular disease. Advances in Chronic Kidney Disease, 2004, 11, 274-293.	0.6	8
51	Intensive lipid lowering with atorvastatin reduces progression of coronary atherosclerosis, as measured by intravascular ultrasound. Evidence-Based Healthcare and Public Health, 2004, 8, 298-301.	0.2	0
52	Low cholesterol, mortality, and quality of life in old age during a 39-year follow-up. Journal of the American College of Cardiology, 2004, 44, 1002-1008.	1.2	31
53	Lipaemia, Inflammation and Atherosclerosis. Drugs, 2004, 64, 19-41.	4.9	59
54	Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge. Expert Review of Cardiovascular Therapy, 2004, 2, 405-415.	0.6	6
55	Los hipolipemiantes tambi�n son efectivos en la reducci3n del riesgo de ictus. FMC Formacion Medica Continuada En Atencion Primaria, 2004, 11, 364.	0.0	0
56	Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clinical Therapeutics, 2004, 26, 1821-1833.	1.1	51
57	Walking, lipids, and lipoproteins: a meta-analysis of randomized controlled trials. Preventive Medicine, 2004, 38, 651-661.	1.6	123
60	The vulnerable atherosclerotic plaque. Cardiovascular Pathology, 2004, 13, 125-138.	0.7	213
61	Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutrition, Metabolism and Cardiovascular Diseases, 2004, 14, 215-224.	1.1	39

#	ARTICLE	IF	CITATIONS
62	Nutrition and prevention of ischemic stroke: present knowledge, limitations and future perspectives. Nutrition, Metabolism and Cardiovascular Diseases, 2004, 14, 97-114.	1.1	14
64	Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology, 2004, 44, 720-732.	1.2	1,207
65	Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions. Lancet, The, 2004, 363, 757-767.	6.3	1,016
66	Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet, The, 2004, 364, 771-777.	6.3	299
67	Age at Natural Menopause and Stroke Mortality. Stroke, 2004, 35, 1548-1551.	1.0	48
68	Genomics-Proteomics and Stroke: Introduction. Stroke, 2004, 35, 2731-2734.	1.0	3
69	Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Current Opinion in Lipidology, 2004, 15, 439-446.	1.2	32
70	In-Hospital Initiation of Lipid-Lowering Therapy. Critical Pathways in Cardiology, 2004, 3, S17-S19.	0.2	0
71	National Cholesterol Education Program Guidelines and Supporting Evidence. Critical Pathways in Cardiology, 2004, 3, S8-S11.	0.2	0
72	Statin policy and target populations: evidence-based or evidence-biased?. Current Opinion in Lipidology, 2004, 15, 381-386.	1.2	2
73	Les effets non lipidiques des statines au cours de l'athérosclérose. Revue De Medecine Interne, 2004, 25, 783-785.	0.6	2
74	Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK. Journal of the Royal Society of Medicine, 2004, 97, 226-229.	1.1	6
75	Birth Weight and Subsequent Cholesterol Levels. JAMA - Journal of the American Medical Association, 2004, 292, 2755.	3.8	136
76	Does the Collaborative Model Improve Care for Chronic Heart Failure?. Medical Care, 2005, 43, 667-675.	1.1	82
77	Lowering LDL Cholesterol: Where Is the End of the Journey?. Cardiology, 2005, 5, 39-50.	0.3	1
78	Physical activity but no cholesterol-lowering for the elderly: probably not. Journal of Hypertension, 2005, 23, 1785-1786.	0.3	1
79	Relative Importance of Borderline and Elevated Levels of Coronary Heart Disease Risk Factors. Annals of Internal Medicine, 2005, 142, 393.	2.0	168
80	Relation of Serum Total Cholesterol and Other Factors to Risk of Cerebral Infarction in Japanese Men With Hypercholesterolemia-The Kyushu Lipid Intervention Study-. Circulation Journal, 2005, 69, 1-6.	0.7	21

#	ARTICLE	IF	CITATIONS
81	Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1363-1370.	0.4	77
82	Model-based development of gemcabene, a new lipid-altering agent. <i>AAPS Journal</i> , 2005, 7, E513-E522.	2.2	65
84	Preventable stroke and stroke prevention. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1638-1645.	1.9	47
85	Obesity: weighing the risk before prescribing. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 259-261.	1.1	2
86	Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 564-573.	1.1	125
87	Suboptimal choices and dosing of statins at start of therapy. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 83-89.	1.1	20
88	Factors influencing clinicians' decisions to prescribe medication to prevent coronary heart disease. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 77-84.	0.7	15
89	The effect of atorvastatin on serum lipoproteins in acromegaly. <i>Clinical Endocrinology</i> , 2005, 62, 650-655.	1.2	12
90	High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. <i>British Journal of Pharmacology</i> , 2005, 144, 933-939.	2.7	38
91	Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert. <i>European Journal of Clinical Nutrition</i> , 2005, 59, S4-S9.	1.3	6
92	Statins and Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1093-1110.	2.4	170
93	Cardiovascular disease in lupus patients: Should all patients be treated with statins and aspirin?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 823-838.	1.4	56
94	Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke. <i>Brain Research</i> , 2005, 1042, 1-5.	1.1	49
95	Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. <i>Brain Research</i> , 2005, 1045, 229-233.	1.1	48
96	A "poly-portfolio" for secondary prevention: A strategy to reduce subsequent events by up to 97% over five years. <i>American Journal of Cardiology</i> , 2005, 95, 373-378.	0.7	44
97	The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. <i>BMC Medicine</i> , 2005, 3, 6.	2.3	99
98	Achieving Cholesterol Target in a Managed Care Organization (ACTION) Trial. <i>Pharmacotherapy</i> , 2005, 25, 360-371.	1.2	30
99	Hypercholesterolemia and inflammation in atherogenesis: Two sides of the same coin. <i>Molecular Nutrition and Food Research</i> , 2005, 49, 995-998.	1.5	70

#	ARTICLE	IF	CITATIONS
100	Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 667-674.	0.8	59
102	Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). <i>Diabetologia</i> , 2005, 48, 2482-2485.	2.9	55
103	Poly-ADP-ribosylation in health and disease. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 739-750.	2.4	115
104	Caloric restriction versus drug therapy to delay the onset of aging diseases and extend life. <i>Age</i> , 2005, 27, 39-48.	3.0	17
105	Statins and the prevention of stroke in diabetes. <i>Current Diabetes Reports</i> , 2005, 5, 1-3.	1.7	1
106	Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients – The PRIMO Study. <i>Cardiovascular Drugs and Therapy</i> , 2005, 19, 403-414.	1.3	1,039
107	The "Statin" wonder of the world: a panacea for all illnesses or a bubble about to burst. <i>Journal of Negative Results in BioMedicine</i> , 2005, 4, 3.	1.4	8
108	Statin therapy should be considered routinely for people with diabetes mellitus. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2005, 22, 233-236.	0.2	0
109	Lipid-modifying drugs. <i>Medical Journal of Australia</i> , 2005, 182, 286-289.	0.8	13
110	Over-the-Counter Statins. <i>Annals of Internal Medicine</i> , 2005, 142, 910.	2.0	39
111	Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin. <i>Thrombosis and Haemostasis</i> , 2005, 93, 8-16.	1.8	57
112	Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. <i>Cmaj</i> , 2005, 173, S1-S25.	0.9	189
113	National Trends in Statin Use by Coronary Heart Disease Risk Category. <i>PLoS Medicine</i> , 2005, 2, e123.	3.9	100
114	Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease. <i>Circulation</i> , 2005, 111, 2906-2912.	1.6	375
115	Contradicted and Initially Stronger Effects in Highly Cited Clinical Research. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 218.	3.8	1,209
117	Arterial Elasticity as Part of a Comprehensive Assessment of Cardiovascular Risk and Drug Treatment. <i>Hypertension</i> , 2005, 46, 217-220.	1.3	83
118	Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy. <i>Archives of Internal Medicine</i> , 2005, 165, 1147.	4.3	437
119	Are the benefits of statins a class effect?. <i>Cmaj</i> , 2005, 172, 1195-1196.	0.9	2

#	ARTICLE	IF	CITATIONS
120	Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. <i>Cmaj</i> , 2005, 172, 1187-1194.	0.9	49
121	The effect of plant stanol- and sterol-enriched foods on lipid metabolism, serum lipids and coronary heart disease. <i>Annals of Clinical Biochemistry</i> , 2005, 42, 254-263.	0.8	58
122	Best practice in primary care pathology: review 1. <i>Journal of Clinical Pathology</i> , 2005, 58, 1016-1024.	1.0	31
123	Secondary Prevention of Ischemic Cerebrovascular Disease. What Is the Evidence?. <i>Angiology</i> , 2005, 56, 539-552.	0.8	3
124	Managing Abnormal Blood Lipids. <i>Circulation</i> , 2005, 112, 3184-3209.	1.6	199
125	Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1897-1910.	0.9	10
126	Cholesterol control in stroke prevention in Italy: a cross-sectional study in family practice. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005, 12, 159-163.	3.1	3
127	Statins and Blood Coagulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 287-294.	1.1	235
128	Lipid and Non-lipid Effects of Statins. <i>Handbook of Experimental Pharmacology</i> , 2005, , 365-388.	0.9	13
129	Cost effectiveness of statins in coronary heart disease. <i>Journal of Epidemiology and Community Health</i> , 2005, 59, 927-933.	2.0	45
130	In-Hospital Initiation of Statin Therapy in Acute Coronary Syndromes. <i>Chest</i> , 2005, 128, 3641-3651.	0.4	16
131	Secondary Prevention of Recurrent Stroke. <i>Stroke</i> , 2005, 36, 218-221.	1.0	47
132	Familial Hypercholesterolemia Patients Treated With Statins at No Increased Risk for Intracranial Vascular Lesions Despite Increased Cholesterol Burden and Extracranial Atherosclerosis. <i>Stroke</i> , 2005, 36, 1572-1574.	1.0	32
133	Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome. <i>Circulation</i> , 2005, 112, 812-818.	1.6	230
134	Impact of lipid treatment on cardiovascular risk reduction: new therapeutic targets. <i>Country Review Ukraine</i> , 2005, 7, L16-L20.	0.8	1
135	Cardiovascular complications of immunosuppressive agents in renal transplant recipients. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 29-44.	1.0	8
139	Plasma glucose goals and therapeutic management in elderly diabetic patients. <i>Diabetes and Metabolism</i> , 2005, 31, 5S58-5S61.	1.4	18
140	The role of lipid management in diabetes. <i>Cardiology Clinics</i> , 2005, 23, 153-164.	0.9	0

#	ARTICLE	IF	CITATIONS
141	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. <i>Heart</i> , 2005, 91, v1-v52.	1.2	731
142	Walking and Non-HDL in Adults: A Meta-Analysis of Randomized Controlled Trials. <i>Preventive Cardiology</i> , 2005, 8, 102-107.	1.1	33
143	Characterization of Ischemic Events and Use of Prescription Antiplatelet and Anticoagulant Agents After Stroke or Transient Ischemic Attack. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2005, 14, 145-151.	0.7	5
144	Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study. <i>Current Therapeutic Research</i> , 2005, 66, 613-629.	0.5	3
145	Treatment of Hypercholesterolemia With Ezetimibe in the Kidney Transplant Population. <i>Transplantation Proceedings</i> , 2005, 37, 1033-1035.	0.3	46
146	Developmental origins of aging in brain and blood vessels: an overview. <i>Neurobiology of Aging</i> , 2005, 26, 281-291.	1.5	64
147	Isocaloric substitution of plant sterol-enriched fat spread for carbohydrate-rich foods in a low-fat, fibre-rich diet decreases plasma low-density lipoprotein cholesterol and increases high-density lipoprotein concentrations. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 337-344.	1.1	5
148	Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. <i>American Heart Journal</i> , 2005, 149, 234-239.	1.2	85
149	Combination Pharmacotherapy for Cardiovascular Disease Prevention. <i>American Journal of Preventive Medicine</i> , 2005, 29, 134-138.	1.6	10
152	Pleiotropic effects of statins. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1292-1294.	1.2	40
153	Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1855-1862.	1.2	397
154	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. <i>Journal of Vascular Surgery</i> , 2005, 42, 829-836.	0.6	176
155	Therapy Insight: potential of statins for cancer chemoprevention and therapy. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 82-89.	4.3	109
156	Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 433-439.	0.5	509
157	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 461-476.	0.6	44
158	Phytosterols/Stanols Lower Cholesterol Concentrations in Familial Hypercholesterolemic Subjects: A Systematic Review with Meta-Analysis. <i>Journal of the American College of Nutrition</i> , 2006, 25, 41-48.	1.1	122
159	Canadian Cardiovascular Society position statement "Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. <i>Canadian Journal of Cardiology</i> , 2006, 22, 913-927.	0.8	271
160	Tratamiento preventivo del ictus. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2006, 18, 20-33.	0.4	0

#	ARTICLE	IF	CITATIONS
161	Efficacy and safety of cholesterol-lowering treatment. <i>Lancet, The</i> , 2006, 367, 469-470.	6.3	12
162	Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. <i>Lancet, The</i> , 2006, 368, 679-686.	6.3	229
163	Inflammation and Atherosclerosis. <i>Stroke</i> , 2006, 37, 1923-1932.	1.0	416
164	Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. <i>Atherosclerosis</i> , 2006, 185, 331-339.	0.4	42
165	Cholestanol: A serum marker to guide LDL cholesterol-lowering therapy. <i>Atherosclerosis</i> , 2006, 184, 247-254.	0.4	20
166	The evolution of European guidelines: Changing the management of cholesterol levels. <i>Atherosclerosis</i> , 2006, 185, 12-20.	0.4	21
167	Association between well-characterized lipoprotein-related genetic variants and carotid intimal medial thickness and stenosis: The Framingham Heart Study. <i>Atherosclerosis</i> , 2006, 189, 222-228.	0.4	21
168	Manitoba Diabetes Care Project: Examining Trends in Diabetes Therapy Prescribing Patterns in Manitoba. <i>Canadian Journal of Diabetes</i> , 2006, 30, 248-255.	0.4	1
169	Les statines : intÃ©rÃ©ts en cardiologie, implications en anesthÃ©sie. <i>Praticien En Anesthesie Reanimation</i> , 2006, 10, 156-165.	0.0	0
170	Overcoming ???Ageism??? Bias in the Treatment of Hypercholesterolaemia. <i>Drug Safety</i> , 2006, 29, 421-448.	1.4	48
171	Fluvastatin and Hepatic Reactions. <i>Drug Safety</i> , 2006, 29, 1163-1172.	1.4	18
172	Effects of adjuvant aromatase inhibitor therapy on lipid profiles. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1653-1662.	1.1	11
173	Missed opportunities in the secondary prevention of myocardial infarction: An assessment of the effects of statin underprescribing on mortality. <i>American Heart Journal</i> , 2006, 151, 969-975.	1.2	43
174	Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: Analysis of the Orbofiban in Patients with Unstable coronary Syndromesâ€”Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. <i>American Heart Journal</i> , 2006, 151, 976.e1-976.e6.	1.2	38
175	Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. <i>Neuroscience Letters</i> , 2006, 408, 189-193.	1.0	26
176	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). <i>International Journal of Cardiology</i> , 2006, 110, 242-250.	0.8	25
177	Effect of <i>Lactobacillus fermentum</i> on serum lipids in subjects with elevated serum cholesterol. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 531-535.	1.1	116
178	Treatment of Hyperlipidemia from Japanese Evidence. <i>Journal of Atherosclerosis and Thrombosis</i> , 2006, 13, 267-280.	0.9	20

#	ARTICLE	IF	CITATIONS
179	Clinicalâ€“pharmacological implications of over-the-counter sales of statins. <i>Future Lipidology</i> , 2006, 1, 17-24.	0.5	0
180	Serum fatty acids as biomarkers of fat intake predict serum cholesterol concentrations in a population-based survey of New Zealand adolescents and adults. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 887-894.	2.2	26
181	Therapeutic Goal Attainment in Patients With Hypertension and Dyslipidemia. <i>Medical Care</i> , 2006, 44, 39-46.	1.1	90
182	Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review. <i>International Journal of Nanomedicine</i> , 2006, 1, 129-147.	3.3	46
183	No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. <i>Clinical Transplantation</i> , 2006, 20, 732-739.	0.8	16
184	Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD). <i>Diabetic Medicine</i> , 2006, 23, 109-112.	1.2	1
185	Cardiovascular mortality attributable to high blood cholesterol in New Zealand. <i>Australian and New Zealand Journal of Public Health</i> , 2006, 30, 252-257.	0.8	5
186	Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. <i>Fundamental and Clinical Pharmacology</i> , 2006, 20, 321-330.	1.0	22
187	The Anglo-Scandinavian Cardiac Outcomes Trial â€“ Blood Pressure Lowering Arm. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 299-307.	0.7	1
188	Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. <i>Journal of Internal Medicine</i> , 2006, 259, 247-258.	2.7	405
189	Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. <i>Journal of Internal Medicine</i> , 2006, 259, 455-461.	2.7	85
190	â€“Hypertensionâ€™ and â€“microalbuminuriaâ€™: The bell tolls for thee. <i>Kidney International</i> , 2006, 69, 22-28.	2.6	64
191	Cardiac event rate in a lifestyle modification program for patients with chronic coronary artery disease. <i>Clinical Cardiology</i> , 2006, 29, 317-321.	0.7	4
192	Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 22, 71-76.	1.0	24
193	ACE-Inhibition for Secondary Prevention of Cardiovascular Eventsâ€”Should We Change Our Recommendation After PEACE?. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 11-12.	1.3	3
194	Low density lipoprotein cholesterol, statins and cardiovascular events: a metaâ€“analysis. <i>Clinical Research in Cardiology</i> , 2006, 95, 393-404.	1.5	57
195	Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. <i>Clinical and Experimental Nephrology</i> , 2006, 10, 201-209.	0.7	4
196	Treatment of lipid disorders in patients with diabetes. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 37-45.	0.4	7

#	ARTICLE	IF	CITATIONS
197	Cholesterol lowering to prevent stroke: Who, when, and how?. Current Treatment Options in Neurology, 2006, 8, 496-502.	0.7	0
199	High Cardiovascular Risk in Patients With Diabetes and the Cardiometabolic Syndrome: Mandate for Statin Therapy. Journal of the Cardiometabolic Syndrome, 2006, 1, 178-183.	1.7	8
200	Effects of a Stanol-Enriched Diet on Plasma Cholesterol and Triglycerides in Patients Treated with Statins. Journal of the American Dietetic Association, 2006, 106, 1564-1569.	1.3	44
201	Statin Safety: An Overview and Assessment of the Dataâ€™2005. American Journal of Cardiology, 2006, 97, S6-S26.	0.7	226
202	Statin Safety: A Systematic Review. American Journal of Cardiology, 2006, 97, S52-S60.	0.7	674
203	Benefit versus Risk in Statin Treatment. American Journal of Cardiology, 2006, 97, S95-S97.	0.7	63
204	Molecular Basis of Differences Among Statins and a Comparison with Antioxidant Vitamins. American Journal of Cardiology, 2006, 98, S34-S41.	0.7	51
206	Role of hyperlipidemia in atherosclerotic plaque formation in the internal carotid artery. Journal of Clinical Ultrasound, 2006, 34, 283-288.	0.4	21
207	Testing pitfalls and summary of guidance in lipid management. BMJ: British Medical Journal, 2006, 333, 83-86.	2.4	12
208	Factors Associated With Geographic Variations in Stroke Incidence Among Older Populations in Four US Communities. Stroke, 2006, 37, 1980-1985.	1.0	18
209	Statins and Cerebral Vasomotor Reactivity. Stroke, 2006, 37, 2446-2448.	1.0	27
210	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. European Heart Journal, 2006, 27, 796-801.	1.0	57
211	The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrology Dialysis Transplantation, 2006, 21, 3106-3114.	0.4	93
212	Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ: British Medical Journal, 2006, 333, 1114-1117.	2.4	178
213	Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies. Quality and Safety in Health Care, 2006, 15, 339-343.	2.5	26
214	Statins and Renal Diseases: From Primary Prevention to Renal Replacement Therapy. Journal of the American Society of Nephrology: JASN, 2006, 17, S148-S152.	3.0	27
215	Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. Journal of Public Health, 2006, 28, 361-369.	1.0	19
216	Benefits, challenges, and registerability of the polypill. European Heart Journal, 2006, 27, 1651-1656.	1.0	88

#	ARTICLE	IF	CITATIONS
217	BIOMEDICINE: Lowering LDL--Not Only How Low, But How Long?. <i>Science</i> , 2006, 311, 1721-1723.	6.0	193
218	A preliminary study of hyperlipidemia in Bangkok school children. <i>Asia-Pacific Journal of Public Health</i> , 2006, 18, 15-19.	0.4	8
219	A 39-Year-Old Woman With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 319.	3.8	0
220	The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006, 13, 523-528.	3.1	7
221	Effects of Past and Recent Blood Pressure and Cholesterol Level on Coronary Heart Disease and Stroke Mortality, Accounting for Measurement Error. <i>American Journal of Epidemiology</i> , 2006, 165, 398-409.	1.6	17
222	Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2006, 13, 646-654.	3.1	35
223	The polypill: at what price would it become cost effective?. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 213-217.	2.0	17
224	Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 322-327.	2.0	107
225	Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2006, 354, 1264-1272.	13.9	2,787
226	The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. <i>Circulation</i> , 2006, 114, 2850-2870.	1.6	346
227	A Critical Evaluation of the Role of Soy Protein and Isoflavone Supplementation in the Control of Plasma Cholesterol Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 772-780.	1.8	76
228	Drug utilization of ezetimibe in rehabilitation centres: registry analysis of factors influencing prescription and effectiveness of treatment. <i>Current Medical Research and Opinion</i> , 2006, 22, 631-639.	0.9	4
229	Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2006, 332, 1115-1124.	2.4	270
230	Effects of Policosanol on Patients with Ischemic Stroke: A Pilot Open Study. <i>Journal of Medicinal Food</i> , 2006, 9, 378-385.	0.8	10
231	Background and Treatment of Metabolic Syndrome: A Therapeutic Challenge. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2006, 10, 206-214.	0.4	6
232	American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. <i>Heart</i> , 2006, 92, 1213-1218.	1.2	24
233	Economic impacts attributable to the early clinical benefit of atorvastatin therapy â€” a US managed care perspective. <i>Current Medical Research and Opinion</i> , 2007, 23, 1517-1529.	0.9	13
234	Which statin, what dose?. <i>Drug and Therapeutics Bulletin</i> , 2007, 45, 33-37.	0.3	4

#	ARTICLE	IF	CITATIONS
235	Are soy foods protective against ischemic stroke?. <i>Future Neurology</i> , 2007, 2, 505-511.	0.9	3
236	The Future of Metabolic Syndrome and Cardiovascular Disease Prevention: Polyhype or Polyhope? Tales from the Polyera. <i>Hormone and Metabolic Research</i> , 2007, 39, 627-631.	0.7	3
237	Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy. <i>Archives of Internal Medicine</i> , 2007, 167, 2296.	4.3	158
238	Could targeted food taxes improve health?. <i>Journal of Epidemiology and Community Health</i> , 2007, 61, 689-694.	2.0	172
239	A Systematic Review and Meta-Analysis of Statin Therapy in Children With Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1803-1810.	1.1	207
240	Systemic effects of chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2007, 1, 75-84.	1.0	10
241	Long-Term Continuation on Cardiovascular Drug Treatment in Patients with Coronary Heart Disease. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1644-1647.	0.9	6
243	Statin-treated familial hypercholesterolemia patients with coronary heart disease and pronounced atherosclerosis do not have more brain lesions than healthy controls in later middle age. <i>Acta Radiologica</i> , 2007, 48, 894-899.	0.5	10
244	Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. <i>Heart</i> , 2007, 93, 945-951.	1.2	23
245	Human cholesterol metabolism and therapeutic molecules. <i>Experimental Physiology</i> , 2007, 93, 27-42.	0.9	72
246	Evaluation of Medical Treatment for Peripheral Arterial Disease in Chinese High-Risk Patients. <i>Circulation Journal</i> , 2007, 71, 95-99.	0.7	18
247	Rates and Risk Factors for Nonadherence to the Medical Regimen After Adult Solid Organ Transplantation. <i>Transplantation</i> , 2007, 83, 858-873.	0.5	494
248	The Impact of Postoperative Discontinuation or Continuation of Chronic Statin Therapy on Cardiac Outcome After Major Vascular Surgery. <i>Anesthesia and Analgesia</i> , 2007, 104, 1326-1333.	1.1	211
250	Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. <i>Yearbook of Cardiology</i> , 2007, 2007, 247-248.	0.0	2
251	Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. <i>European Heart Journal</i> , 2007, 28, 1977-1983.	1.0	31
253	Reply to Drs Vos, Ravnskov, Mascitelli and Pezzetta. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, e21-e23.	1.1	0
254	Blood Pressure and Lipid Goal Attainment in the Hypertensive Population in the Primary Care Setting in Spain. <i>Journal of Clinical Hypertension</i> , 2007, 9, 324-329.	1.0	41
255	Treatment of Hypertension and Dyslipidemia or Their Combination Among US Managed-Care Patients. <i>Journal of Clinical Hypertension</i> , 2007, 9, 684-691.	1.0	12

#	ARTICLE	IF	CITATIONS
256	A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. <i>Clinical Therapeutics</i> , 2007, 29, 242-252.	1.1	32
257	Prevalence and treatment of dyslipidemia in canadian primary care: A retrospective cohort analysis. <i>Clinical Therapeutics</i> , 2007, 29, 742-750.	1.1	40
258	Statin and statin+fibrate use was significantly associated with increased myositis risk in a managed care population. <i>Journal of Clinical Epidemiology</i> , 2007, 60, 812-818.	2.4	63
259	Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT. <i>International Journal of Cardiology</i> , 2007, 119, 48-53.	0.8	66
260	Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2007, 195, 339-347.	0.4	99
261	Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. <i>Lancet, The</i> , 2007, 370, 2054-2062.	6.3	293
262	A Model for Assessing the Cost-Effectiveness of Atorvastatin and Simvastatin in Achieving Canadian Low-Density Lipoprotein Cholesterol Targets. <i>Clinical Therapeutics</i> , 2007, 29, 519-528.	1.1	9
263	Preventing cardiovascular disease among Canadians: What are the potential benefits of treating hypertension or dyslipidemia?. <i>Canadian Journal of Cardiology</i> , 2007, 23, 467-473.	0.8	27
264	Letter to the editor. <i>Canadian Journal of Cardiology</i> , 2007, 23, 481-482.	0.8	1
265	The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects. <i>Lipids in Health and Disease</i> , 2007, 6, 11.	1.2	40
266	Atorvastatin. <i>Drugs</i> , 2007, 67, 3-15.	4.9	61
267	System of Objectified Judgement Analysis (SOJA) as a tool in rational and transparent drug-decision making. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, S5-S14.	0.9	11
268	Atorvastatin. <i>Pharmacoeconomics</i> , 2007, 25, 1031-1053.	1.7	22
269	Should We Encourage Over-The-Counter Statins?. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 299-302.	1.0	5
270	Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning. <i>Pharmacological Reviews</i> , 2007, 59, 418-458.	7.1	631
271	Normal Sâ€œcholesterol indicates unchanged Sâ€œLDL, Sâ€œHDL and Sâ€œtriglycerides in patients with previously acceptable blood lipids. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2007, 67, 498-506.	0.6	2
272	Valutazione economica di rosuvastatina nel trattamento di prevenzione delle malattie cardiovascolari: una revisione sistematica della letteratura. <i>Pharmacoeconomics Italian Research Articles</i> , 2007, 9, 45-58.	0.2	0
273	Statins: An essential component in the management of carotid artery disease. <i>Journal of Vascular Surgery</i> , 2007, 46, 373-386.e9.	0.6	79

#	ARTICLE	IF	CITATIONS
274	Les bi- et trithÃ©rapies hypolipÃ©miantes : quelles indications, pour quels bÃ©nÃ©fices/risques. <i>Medecine Des Maladies Metaboliques</i> , 2007, 1, 70-75.	0.1	0
275	Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteaemic response to simvastatin and fluvastatin. <i>Pharmacological Research</i> , 2007, 55, 310-317.	3.1	71
276	Safety Profile of Rosuvastatin. <i>Drug Safety</i> , 2007, 30, 157-170.	1.4	37
277	Squalene Synthase Inhibitors. <i>Drugs</i> , 2007, 67, 11-16.	4.9	66
278	Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease. <i>Clinical Drug Investigation</i> , 2007, 27, 591-604.	1.1	18
279	Beyond Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1735-1741.	1.2	115
280	Statins and Stroke Prevention. <i>Cerebrovascular Diseases</i> , 2007, 24, 170-182.	0.8	61
281	Factors Associated with Findings of Published Trials of Drug-Drug Comparisons: Why Some Statins Appear More Efficacious than Others. <i>PLoS Medicine</i> , 2007, 4, e184.	3.9	215
283	An Educational Intervention, Involving Feedback of Routinely Collected Computer Data, to Improve Cardiovascular Disease Management in UK Primary Care. <i>Methods of Information in Medicine</i> , 2007, 46, 57-62.	0.7	28
285	Effects of chronic hyperglycaemia on incident stroke in Hong Kong Chinese patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 220-226.	1.7	11
286	Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 132-143.	0.9	50
287	The prevalence of newly diagnosed hyperlipidaemia in men with erectile dysfunction. <i>BJU International</i> , 2007, 100, 357-361.	1.3	19
288	Impact of adherence to statins on coronary artery disease in primary prevention. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 698-708.	1.1	86
289	Study highlights need for considered clinical approach to statin switching. <i>International Journal of Clinical Practice</i> , 2007, 61, 880-880.	0.8	0
290	Cholesterol-lowering management of stroke: Inconsistencies of evidence and practice. <i>Nutrition and Dietetics</i> , 2007, 64, 37-42.	0.9	0
291	Comparing primary prevention with secondary prevention to explain decreasing Coronary Heart Disease death rates in Ireland, 1985-2000. <i>BMC Public Health</i> , 2007, 7, 117.	1.2	25
292	NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. <i>European Journal of Pharmacology</i> , 2007, 570, 115-124.	1.7	43
293	Understanding diet-gene interactions: Lessons from studying nutrigenomics and cardiovascular disease. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2007, 622, 7-13.	0.4	16

#	ARTICLE	IF	CITATIONS
294	Patterns and predictors of statin use after coronary artery bypass graft surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 134, 932-938.	0.4	52
296	MRI at 3 Tesla detects no evidence for ischemic brain damage in intensively treated patients with homozygous familial hypercholesterolemia. <i>Neuroradiology</i> , 2007, 49, 927-931.	1.1	4
298	Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels. <i>European Journal of Epidemiology</i> , 2007, 22, 429-438.	2.5	23
299	Predictors of Adherence to Statins for Primary Prevention. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 311-316.	1.3	131
301	Statin therapy to prevent stroke in the elderly. <i>Current Cardiovascular Risk Reports</i> , 2007, 1, 324-329.	0.8	0
302	Estimating the Impact of Adding C-Reactive Protein as a Criterion for Lipid Lowering Treatment in the United States. <i>Journal of General Internal Medicine</i> , 2007, 22, 197-204.	1.3	6
303	Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering. <i>International Urology and Nephrology</i> , 2008, 40, 165-170.	0.6	16
304	The Heart of New Ulm: A Vision for the Future. <i>Journal of Cardiovascular Translational Research</i> , 2008, 1, 310-316.	1.1	23
305	Statin treatment for rheumatoid arthritis: a promising novel indication. <i>Clinical Rheumatology</i> , 2008, 27, 281-287.	1.0	56
306	Effects of the introduction of fixed prices for statins on lipid levels in Germany. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2008, 16, 215-219.	0.8	6
307	Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients. <i>International Journal for Equity in Health</i> , 2008, 7, 16.	1.5	18
308	Estimation of risk factor associations when the response is influenced by medication use: An imputation approach. <i>Statistics in Medicine</i> , 2008, 27, 5039-5053.	0.8	27
309	Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. <i>Liver Transplantation</i> , 2008, 14, 159-172.	1.3	250
310	Human cholesterol metabolism and therapeutic molecules. <i>Experimental Physiology</i> , 2008, 93, 27-42.	0.9	95
311	Newly identified loci that influence lipid concentrations and risk of coronary artery disease. <i>Nature Genetics</i> , 2008, 40, 161-169.	9.4	1,488
312	Cost-Effectiveness of Rosuvastatin in the Prevention of Ischemic Heart Disease in Portugal. <i>Value in Health</i> , 2008, 11, 154-159.	0.1	12
313	Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting. <i>Diabetic Medicine</i> , 2008, 25, 909-915.	1.2	12
314	Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 775-786.	1.1	24

#	ARTICLE	IF	CITATIONS
315	The human paraoxonaseâ€1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 366-374.	1.1	51
317	Study Design and Statistical Issues in Pharmacogenetics Research. <i>Methods in Pharmacology and Toxicology</i> , 2008, , 185-206.	0.1	0
319	Risk Functions and the Primary Prevention of Cardiovascular Disease. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 404-416.	0.4	7
320	Rosuvastatin: efficacy, safety and clinical effectiveness. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2145-2160.	0.9	36
321	Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells. <i>International Journal of Cardiology</i> , 2008, 127, 33-39.	0.8	17
323	Class effects of statins in elderly patients with congestive heart failure: A population-based analysis. <i>American Heart Journal</i> , 2008, 155, 316-323.	1.2	28
324	Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008, 18, 483-491.	1.1	21
325	Combination Polypharmacy for Cardiovascular Disease Prevention in Men: A Decision Analysis and Costâ€Effectiveness Model. <i>Preventive Cardiology</i> , 2008, 11, 36-41.	1.1	13
326	Disease management programmes for patients with coronary heart diseaseâ€An empirical study of German programmes. <i>Health Policy</i> , 2008, 88, 176-185.	1.4	26
327	Relation between age and coronary heart disease (CHD) risk in Asian Indian patients with diabetes: A cross-sectional and prospective cohort study. <i>Diabetes Research and Clinical Practice</i> , 2008, 81, 243-249.	1.1	10
328	Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey. <i>Atherosclerosis</i> , 2008, 197, 710-717.	0.4	63
329	Estimated prevalence of uncontrolled hypertension and multiple cardiovascular risk factors and their associated risk of coronary heart disease in the United States. <i>Journal of the American Society of Hypertension</i> , 2008, 2, 44-53.	2.3	6
330	Cholesterol, statins, and mortality. <i>Lancet, The</i> , 2008, 371, 1161-1162.	6.3	3
331	Can we eliminate inequalities in coronary disease? Absolutely. <i>Lancet, The</i> , 2008, 372, 1612-1613.	6.3	6
332	Chapter 8 Atherogenic Lipoprotein Subprofiling. <i>Advances in Clinical Chemistry</i> , 2008, , 295-317.	1.8	10
333	Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: Resolved and unresolved issues. <i>Canadian Journal of Cardiology</i> , 2008, 24, 293-300.	0.8	15
334	Une hypercholestÃ©rolÃ©mie familiale chez lâ€™enfant. <i>Medecine Des Maladies Metaboliques</i> , 2008, 2, 43-45.	0.1	0
335	Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. <i>Current Medical Research and Opinion</i> , 2008, 24, 2777-2784.	0.9	3

#	ARTICLE	IF	CITATIONS
336	Clinical pharmacology in special populations: the extremes of age. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 467-469.	1.3	6
337	Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. <i>Angiology</i> , 2008, 59, 36-46.	0.8	9
338	L'uso delle DDD reference based per la valutazione della compliance terapeutica nel trattamento con statine. <i>Pharmacoeconomics Italian Research Articles</i> , 2008, 10, 77-88.	0.2	1
339	Valutazione di un risultato del trattamento con statine: il caso dell'ASL di Foligno (PG). <i>Pharmacoeconomics Italian Research Articles</i> , 2008, 10, 123-136.	0.2	1
340	Chapter 63 The future of stroke prevention by risk factor modification. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 94, 1261-1276.	1.0	8
341	Cardiovascular risk prediction: are we there yet?. <i>Heart</i> , 2008, 94, 1-3.	1.2	39
342	Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management. <i>Practical Neurology</i> , 2008, 8, 141-157.	0.5	11
343	Can Cheap Generic Statins Achieve National Cholesterol Lowering Targets?. <i>Journal of Health Services Research and Policy</i> , 2008, 13, 99-102.	0.8	5
344	Unraveling Pleiotropic Effects Of Statins. <i>Circulation Research</i> , 2008, 103, 334-336.	2.0	33
345	Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. <i>Current Medical Research and Opinion</i> , 2008, 24, 1823-1832.	0.9	23
346	NICE's simplified approach to lipids will not work. <i>BMJ: British Medical Journal</i> , 2008, 336, 1324.1-1324.	2.4	3
347	Familial hypercholesterolemia: current treatment and advances in management. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 567-581.	0.6	66
348	Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2008, 336, 645-651.	2.4	382
349	Trends in Statin Use and Low-Density Lipoprotein Cholesterol Levels Among US Adults: Impact of the 2001 National Cholesterol Education Program Guidelines. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1208-1215.	0.9	200
350	Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2008, 2, 387-405.	1.0	12
351	Disorders of Lipid Metabolism. <i>Fundamental and Clinical Cardiology</i> , 2008, , 159-178.	0.0	1
352	Chapter 19 Costs and health care system issues. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 92, 373-388.	1.0	0
353	Heartwatch: a secondary prevention programme in primary care in Ireland. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 651-656.	3.1	12

#	ARTICLE	IF	CITATIONS
354	Estimating the cardiovascular mortality burden attributable to the European Common Agricultural Policy on dietary saturated fats. <i>Bulletin of the World Health Organization</i> , 2008, 86, 535-541.	1.5	64
355	A Model for Ischaemic Heart Disease and Stroke II: Modelling Obesity. <i>Annals of Actuarial Science</i> , 2008, 3, 83-103.	1.0	7
356	Applications of statins in cardiothoracic surgery: more than just lipid-lowering. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 33, 377-390.	0.6	28
357	Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. <i>Journal of Psychopharmacology</i> , 2008, 22, 33-38.	2.0	44
358	A Model for Ischaemic Heart Disease and Stroke III: Applications. <i>Annals of Actuarial Science</i> , 2008, 3, 105-119.	1.0	7
359	A Model for Ischaemic Heart Disease and Stroke I: The Model. <i>Annals of Actuarial Science</i> , 2008, 3, 45-81.	1.0	7
360	Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3671-3689.	1.8	164
361	The use of fluvastatin in cardiovascular risk management. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1407-1414.	0.9	5
362	A systematic review of the association between cardiovascular risk factors and regular consumption of oats. <i>British Food Journal</i> , 2008, 110, 1119-1132.	1.6	19
363	Hypercholesterolaemia and its management. <i>BMJ: British Medical Journal</i> , 2008, 337, a993-a993.	2.4	116
364	Does initial breastfeeding lead to lower blood cholesterol in adult life? A quantitative review of the evidence. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 305-314.	2.2	194
365	Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 878-887.	0.6	14
366	Safety of statins. <i>Current Opinion in Lipidology</i> , 2008, 19, 558-562.	1.2	48
367	The independent relationship between triglycerides and coronary heart disease. <i>Vascular Health and Risk Management</i> , 2008, , 89.	1.0	33
368	The hidden cost of switching medication. <i>British Journal of Health Care Management</i> , 2008, 14, 324-328.	0.1	0
369	Statin Reduces C-Reactive Protein and Interleukin-6 in Normocholesterolemic Patients with Acute Coronary Syndrome. <i>Chonnam Medical Journal</i> , 2008, 44, 13.	0.1	2
370	Low drug doses may improve outcomes in chronic disease. <i>Medical Journal of Australia</i> , 2009, 191, 511-513.	0.8	19
371	HMG CoA reductase inhibitors (statins) for dialysis patients. , 2009, , CD004289.		65

#	ARTICLE	IF	CITATIONS
372	Efficacy and safety of rosuvastatin in the management of dyslipidemia. <i>Vascular Health and Risk Management</i> , 2009, 5, 343.	1.0	26
373	Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2009, 5, 369.	1.0	23
374	Statins in Neurological Disorders: Mechanisms and Therapeutic Value. <i>Scientific World Journal</i> , The, 2009, 9, 1242-1259.	0.8	32
375	Admixture mapping of quantitative trait loci for blood lipids in African-Americans. <i>Human Molecular Genetics</i> , 2009, 18, 2091-2098.	1.4	29
376	Small changes in snacking behaviour: the potential impact on CVD mortality. <i>Public Health Nutrition</i> , 2009, 12, 871-876.	1.1	30
377	Large scale replication analysis of loci associated with lipid concentrations in a Japanese population. <i>Journal of Medical Genetics</i> , 2009, 46, 370-374.	1.5	81
378	The polypill story from a ringside seat. <i>Journal of the Royal Society of Medicine</i> , 2009, 102, 509-512.	1.1	6
379	The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 96-97.	3.3	14
380	The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors. <i>PLoS Medicine</i> , 2009, 6, e1000058.	3.9	1,529
381	Metabolic Consequences of Sleep-Disordered Breathing. <i>ILAR Journal</i> , 2009, 50, 289-306.	1.8	88
382	Use and cost of branded and generic drugs in patients with coronary heart disease—results from a prospective survey of 1008 patients in two London hospitals. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2009, 102, 843-849.	0.2	4
383	Atorvastatin Treatment Is Associated With Less Augmentation of the Carotid Pressure Waveform in Hypertension. <i>Hypertension</i> , 2009, 54, 1009-1013.	1.3	35
384	The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 371-376.	3.1	11
385	Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. <i>Journal of Lipid Research</i> , 2009, 50, 1463-1471.	2.0	72
386	White matter hyperintensities on T2-weighted MRI images among DNA-verified older familial hypercholesterolemia patients. <i>Acta Radiologica</i> , 2009, 50, 320-326.	0.5	8
387	Identification of Genetic Variants Associated With Response to Statin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1310-1315.	1.1	83
388	Is Lipid Control Necessary in Hemodialysis Patients?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, S95-S101.	2.2	23
389	Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 438-444.	3.1	14

#	ARTICLE	IF	CITATIONS
390	Issues to consider in the pharmaceutical development of a cardiovascular polypill. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 112-119.	3.3	31
391	Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 101-110.	3.3	64
392	Major Lipids, Apolipoproteins, and Risk of Vascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1993.	3.8	2,205
393	Metabolic syndrome abating the beneficial effect of pravastatin treatment on adhesion of endothelium by monocytes in subjects with hypercholesterolemia. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 416-420.	1.5	4
394	Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). <i>BMC Cardiovascular Disorders</i> , 2009, 9, 55.	0.7	43
395	Characteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in Disease Management Program versus those in routine care: LUTZ registry. <i>BMC Public Health</i> , 2009, 9, 280.	1.2	14
396	Low-Density Lipoprotein Reduction and Magnitude of Cardiovascular Risk Reduction. <i>Preventive Cardiology</i> , 2009, 12, 80-87.	1.1	9
397	The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. <i>Clinical Therapeutics</i> , 2009, 31, 236-244.	1.1	144
398	Medicinal chemistry strategies in follow-on drug discovery. <i>Drug Discovery Today</i> , 2009, 14, 516-522.	3.2	40
399	Behavioral and quantitative mitochondrial proteome analyses of the effects of simvastatin: implications for models of neural degeneration. <i>Journal of Neural Transmission</i> , 2009, 116, 791-806.	1.4	17
400	Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. <i>Diabetologia</i> , 2009, 52, 50-59.	2.9	70
401	Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 927-933.	0.8	8
402	Impact of better adherence to statin agents in the primary prevention of coronary artery disease. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 1013-1024.	0.8	91
403	A randomized, multicentre, open-label, parallel-group trial to compare the efficacy and safety profile of daming capsule in patients with hypercholesterolemia. <i>Phytotherapy Research</i> , 2009, 23, 1039-1042.	2.8	24
404	Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina. <i>Cost Effectiveness and Resource Allocation</i> , 2009, 7, 10.	0.6	51
405	Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. <i>Clinical Endocrinology</i> , 2009, 70, 815-828.	1.2	69
406	Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. <i>Journal of Internal Medicine</i> , 2009, 265, 568-580.	2.7	183
407	Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. <i>Journal of Internal Medicine</i> , 2009, 265, 698-707.	2.7	39

#	ARTICLE	IF	CITATIONS
408	Gender difference of association between LDL cholesterol concentrations and mortality from coronary heart disease amongst Japanese: the Ibaraki Prefectural Health Study. <i>Journal of Internal Medicine</i> , 2010, 267, 576-587.	2.7	35
409	Adding a Medicine to the WHO Model List of Essential Medicines. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 237-239.	2.3	14
410	Statin treatment after a recent TIA or stroke: is effectiveness shown in randomized clinical trials also observed in everyday clinical practice?. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 15-20.	1.0	9
411	Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 966-977.	2.2	42
412	Potential Health Benefits and Medical Cost Savings from Calorie, Sodium, and Saturated Fat Reductions in the American Diet. <i>American Journal of Health Promotion</i> , 2009, 23, 412-422.	0.9	88
413	Prevalence of use and potential impact of increased use of primary care interventions to prevent cardiovascular hospitalizations in patients with diabetes. <i>Diabetes Research and Clinical Practice</i> , 2009, 85, 328-334.	1.1	3
414	Retinal Vascular Caliber: Systemic, Environmental, and Genetic Associations. <i>Survey of Ophthalmology</i> , 2009, 54, 74-95.	1.7	351
415	26 Years of LDL "Apheresis: A review of experience. <i>Transfusion and Apheresis Science</i> , 2009, 41, 49-59.	0.5	40
416	Statins in Ischemic Stroke: Just Low-Density Lipoprotein Lowering or More?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2009, 18, 124-127.	0.7	26
417	LDL-cholesterol differences predicted survival benefit in statin trials by the surrogate threshold effect (STE). <i>Journal of Clinical Epidemiology</i> , 2009, 62, 328-336.	2.4	13
418	Not so choppy SEAS. <i>Journal of Clinical Lipidology</i> , 2009, 3, 11-13.	0.6	1
419	Effects on Coronary Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol with Statins. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 109-115.	1.0	18
421	Statins and stroke prevention. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1231-1243.	0.6	20
422	Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. <i>BMJ</i> ; <i>British Medical Journal</i> , 2009, 338, b1665-b1665.	2.4	2,170
423	Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. <i>Current Medical Research and Opinion</i> , 2009, 25, 2621-2629.	0.9	7
424	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. , 2009, , CD007784.		84
425	Statin Therapy in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2009, 27, 25-37.	1.7	26
426	Limitations of statin monotherapy for the treatment of dyslipidemia: a projection based on the Canadian lipid study "observational. <i>Current Medical Research and Opinion</i> , 2009, 25, 47-55.	0.9	7

#	ARTICLE	IF	CITATIONS
427	Clinical experience with ezetimibe/simvastatin in a Mediterranean population. <i>Current Medical Research and Opinion</i> , 2009, 25, 2571-2576.	0.9	31
428	Surrogate markers in clinical trials—Challenges and opportunities. <i>Atherosclerosis</i> , 2009, 206, 8-16.	0.4	49
429	Perioperative Statin Therapy Is Associated With a Significant and Dose-Dependent Reduction of Adverse Cardiovascular Outcomes After Coronary Artery Bypass Graft Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2009, 23, 633-638.	0.6	39
430	International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 472-480.	3.1	13
431	Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. <i>Lancet, The</i> , 2009, 373, 929-940.	6.3	737
432	Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. <i>Lancet, The</i> , 2009, 373, 1341-1351.	6.3	422
433	The Indian Polycap Study (TIPS). <i>Lancet, The</i> , 2009, 374, 781.	6.3	17
434	The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2009, 338, b2376-b2376.	2.4	650
435	A Model for Integrating a Mind/Body Approach to Cardiac Rehabilitation. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2009, 29, 230-238.	1.2	26
436	Myalgia in Patients on High-Dose and Low-to-Moderate Dose Statin Therapy. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 202-206.	0.5	1
438	Interventions in the management of serum lipids for preventing stroke recurrence. <i>The Cochrane Library</i> , 2019, 2019, CD002091.	1.5	59
439	Lipid Profile Components and Risk of Ischemic Stroke. <i>Archives of Neurology</i> , 2009, 66, 1400-6.	4.9	69
440	HMG CoA reductase inhibitors (statins) for dialysis patients. , 2009, , CD004289.		9
442	Variation in the Net Benefit of Aggressive Cardiovascular Risk Factor Control Across the US Population of Patients With Diabetes Mellitus. <i>Archives of Internal Medicine</i> , 2010, 170, 1037.	4.3	52
444	Support of drug therapy using functional foods and dietary supplements: focus on statin therapy. <i>British Journal of Nutrition</i> , 2010, 103, 1260-1277.	1.2	38
445	Secondary Stroke Prevention: Practice Patterns in a Tertiary Care Stroke Service. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 245-251.	0.3	6
446	Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. <i>Yearbook of Cardiology</i> , 2010, 2010, 100-102.	0.0	0
449	Statin prescription in men and women at cardiovascular risk: to whom and when?. <i>Current Opinion in Cardiology</i> , 2010, 25, 484-489.	0.8	17

#	ARTICLE	IF	CITATIONS
450	Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease. <i>Annals of Internal Medicine</i> , 2010, 152, 69.	2.0	117
451	Attainment of combined optimal lipid values: a paradigm shift in the management of dyslipidemia. <i>Clinical Lipidology</i> , 2010, 5, 527-541.	0.4	2
452	Phytosterol tablets reduce human LDL-cholesterol. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 889-896.	1.2	30
453	Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography. <i>European Radiology</i> , 2010, 20, 2824-2833.	2.3	49
456	Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. <i>Clinical Research in Cardiology</i> , 2010, 99, 723-733.	1.5	38
457	A French approach to cost-effectiveness analysis?. <i>European Journal of Health Economics</i> , 2010, 11, 521-523.	1.4	7
458	Systematic review on evidence of the effectiveness of cholesterol-lowering drugs. <i>Advances in Therapy</i> , 2010, 27, 348-364.	1.3	20
459	Recent Findings from Mendelian Randomization Studies of Cardiovascular Disease. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 429-436.	0.8	1
460	Polypill: Lights and Shadows. <i>Current Hypertension Reports</i> , 2010, 12, 276-281.	1.5	7
461	Coronary Risk Assessment by Point-Based vs. Equation-Based Framingham Models: Significant Implications for Clinical Care. <i>Journal of General Internal Medicine</i> , 2010, 25, 1145-1151.	1.3	17
462	Can a Statin Neutralize the Cardiovascular Risk of Unhealthy Dietary Choices?. <i>American Journal of Cardiology</i> , 2010, 106, 587-592.	0.7	17
463	Statin Therapy in Primary Prevention: New Insights Regarding Women and the Elderly. <i>American Journal of Cardiology</i> , 2010, 106, 1357-1359.	0.7	3
465	Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. <i>Clinical Therapeutics</i> , 2010, 32, 300-310.	1.1	76
466	Highly stereoselective hydrogenations as key steps in the total synthesis of statins. <i>Chirality</i> , 2010, 22, 534-541.	1.3	19
467	Evaluating gene by sex and age interactions on cardiovascular risk factors in Brazilian families. <i>BMC Medical Genetics</i> , 2010, 11, 132.	2.1	10
468	Diminishing Efficacy of Combination Therapy, Response Heterogeneity, and Treatment Intolerance Limit the Attainability of Tight Risk Factor Control in Patients with Diabetes. <i>Health Services Research</i> , 2010, 45, 437-456.	1.0	26
469	Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical Setting. <i>Value in Health</i> , 2010, 13, 87-94.	0.1	53
470	Projected Cost-Effectiveness of Ezetimibe/Simvastatin Compared with Doubling the Statin Dose in the United Kingdom: Findings from the INFORCE Study. <i>Value in Health</i> , 2010, 13, 726-734.	0.1	20

#	ARTICLE	IF	CITATIONS
471	The challenge of polypharmacy in cardiovascular medicine. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 9-17.	1.0	62
472	The polypill in the primary prevention of cardiovascular disease. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 29-35.	1.0	11
473	A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (â€˜polypillâ€™™) on cardiovascular risk factors. <i>International Journal of Clinical Practice</i> , 2010, 64, 1220-1227.	0.8	113
474	Attainment of Canadian and European guidelinesâ€™™ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. <i>International Journal of Clinical Practice</i> , 2010, 64, 1765-1772.	0.8	4
475	Generic and therapeutic substitutions in the UK: are they a good thing?. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 335-341.	1.1	127
476	Effects of atorvastatin on circulating CD34+/CD133+/ CD45â€™ progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. <i>Journal of Internal Medicine</i> , 2010, 267, 385-393.	2.7	42
477	A systematic review and meta-analysis on the therapeutic equivalence of statins. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 139-151.	0.7	272
478	Statins and neuroprotection. <i>Annals of the New York Academy of Sciences</i> , 2010, 1199, 69-76.	1.8	130
479	Low density lipoproteinâ€™cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 540-544.	2.2	7
480	Association of statin and nonsteroidal antiâ€™inflammatory drug use with prostate cancer outcomes: results from CaPSURE. <i>BJU International</i> , 2010, 106, 627-632.	1.3	38
481	A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials. <i>PLoS ONE</i> , 2010, 5, e8580.	1.1	17
482	High Dose Statins: Is it Beneficial over Conventional Dose of Statin in Acute Coronary Syndrome?. <i>Cardiovascular Journal</i> , 2010, 2, 245-251.	0.0	0
483	Gender Differences in Cardiovascular Disease: Hormonal and Biochemical Influences. <i>Reproductive Sciences</i> , 2010, 17, 511-531.	1.1	155
484	Can lipid abnormalities predict renal disease in patients with diabetes?. <i>Clinical Lipidology</i> , 2010, 5, 151-155.	0.4	1
485	Encouraging appropriate treatment for familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2010, 5, 339-354.	0.4	12
486	The Role of Usual Source of Care in Cholesterol Treatment. <i>Journal of the American Board of Family Medicine</i> , 2010, 23, 179-185.	0.8	16
487	Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 2653-2659.	0.8	146
488	Reply to H.W. Daniell and to L. Azoulay and S. Suissa. <i>Journal of Clinical Oncology</i> , 2010, 28, e645-e646.	0.8	0

#	ARTICLE	IF	CITATIONS
489	Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. <i>Journal of Lipid Research</i> , 2010, 51, 3342-3349.	2.0	41
490	Predictors of Nonadherence to Statins: A Systematic Review and Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1410-1421.	0.9	267
491	EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 530-540.	3.1	193
492	The Association Between Achieving Low-Density Lipoprotein Cholesterol (LDL-C) Goal and Statin Treatment in an Employee Population. <i>Population Health Management</i> , 2010, 13, 1-8.	0.8	11
493	Pharmacotherapy of dyslipidemias in the adult population. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 3041-3052.	0.9	8
494	Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1948-1950.	4.3	12
495	Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. <i>Current Medical Research and Opinion</i> , 2010, 26, 2833-2839.	0.9	13
496	Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. <i>Current Medical Research and Opinion</i> , 2010, 26, 529-536.	0.9	45
497	A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women. <i>Journal of Lipid Research</i> , 2010, 51, 625-634.	2.0	19
498	Primary care research and clinical practice: cardiovascular disease. <i>Postgraduate Medical Journal</i> , 2010, 86, 696-703.	0.9	6
499	Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. <i>Journal of Epidemiology and Community Health</i> , 2010, 64, 109-113.	2.0	35
500	Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. <i>Current Medical Research and Opinion</i> , 2010, 26, 25-36.	0.9	27
501	Epidemiology of Cardiovascular Disease in Type 2 Diabetes: The Indian Scenario. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 158-170.	1.3	71
502	Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 20, 315-333.	0.4	19
503	Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. <i>Current Medical Research and Opinion</i> , 2010, 26, 445-454.	0.9	66
504	A Novel Approach to Quality Improvement in a Safety-Net Practice: Concurrent Peer Review Visits. <i>Journal of the National Medical Association</i> , 2010, 102, 1231-1236.	0.6	16
505	Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden. <i>Current Medical Research and Opinion</i> , 2010, 26, 389-396.	0.9	4
507	Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. <i>Journal of Clinical Lipidology</i> , 2010, 4, 279-287.	0.6	37

#	ARTICLE	IF	CITATIONS
508	Observational study of adherence to European clinical practice guidelines for the management of acute coronary syndrome in revascularized versus non-revascularized patients – the CONNECT Study. Archives of Cardiovascular Diseases, 2010, 103, 437-446.	0.7	12
509	The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients. European Journal of Internal Medicine, 2010, 21, 293-296.	1.0	11
510	A cluster randomised controlled trial of pharmacist led Statin Outreach Support (SOS) in primary care: Design and baseline characteristics. Contemporary Clinical Trials, 2010, 31, 303-311.	0.8	7
511	Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thrombosis Research, 2010, 125, 382-386.	0.8	23
512	The effects of atorvastatin on memory deficit and seizure susceptibility in pentylentetrazole-kindled rats. Epilepsy and Behavior, 2010, 19, 284-289.	0.9	25
513	Association of statin prescription with small abdominal aortic aneurysm progression. American Heart Journal, 2010, 159, 307-313.	1.2	152
514	Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis, 2010, 209, 189-194.	0.4	250
515	Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis, 2010, 210, 353-361.	0.4	250
516	Lactobacillus acidophilus CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters. Journal of Dairy Science, 2010, 93, 5048-5058.	1.4	69
517	Advancing therapy for hypercholesterolemia. Expert Opinion on Pharmacotherapy, 2010, 11, 1659-1672.	0.9	26
518	The Polypill in the Prevention of Cardiovascular Diseases. Circulation, 2010, 122, 2078-2088.	1.6	152
519	Atorvastatin: safety and tolerability. Expert Opinion on Drug Safety, 2010, 9, 667-674.	1.0	38
520	Premature cardiovascular events and mortality in south Asians with type 2 diabetes in the United Kingdom Asian Diabetes Study – effect of ethnicity on risk. Current Medical Research and Opinion, 2010, 26, 1873-1879.	0.9	73
521	The polypill concept. Postgraduate Medical Journal, 2010, 86, 257-260.	0.9	23
522	The Cost Effectiveness of Statin Therapies in Spain in 2010, after the Introduction of Generics and Reference Prices. American Journal of Cardiovascular Drugs, 2010, 10, 369-382.	1.0	23
523	Primary prevention using statins: to be or not to be?. Current Medical Research and Opinion, 2010, 26, 2701-2706.	0.9	3
524	Long-Term Follow-Up of Statin Treatment in a Cohort of Children with Familial Hypercholesterolemia. Paediatric Drugs, 2011, 13, 267-275.	1.3	42
525	Dietary Fatty Acids and Cardiovascular Health – An Ongoing Controversy. Annals of Nutrition and Metabolism, 2011, 58, 66-67.	1.0	7

#	ARTICLE	IF	CITATIONS
526	Impact of HMG-CoA Reductase Inhibitor (Statin) Use on Blood Loss During Robot-Assisted and Open Radical Prostatectomy. <i>Journal of Endourology</i> , 2011, 25, 1427-1433.	1.1	2
528	HDL-cholesterol et approche thérapeutique. <i>Archives of Cardiovascular Diseases Supplements</i> , 2011, 3, 273-279.	0.0	0
529	Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study. <i>Pharmacological Research</i> , 2011, 64, 393-396.	3.1	14
531	Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. <i>American Heart Journal</i> , 2011, 161, 719-725.	1.2	40
532	Cholesterol Management in the United States: The National Health and Nutrition Examination Survey, 1999 to 2006. <i>Annals of Epidemiology</i> , 2011, 21, 318-326.	0.9	12
533	Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care. <i>Contemporary Clinical Trials</i> , 2011, 32, 909-915.	0.8	38
534	Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?. <i>Canadian Journal of Cardiology</i> , 2011, 27, 146-151.	0.8	64
535	Estimating the Benefits of Patient and Physician Adherence to Cardiovascular Prevention Guidelines: The MyHealthCheckup Survey. <i>Canadian Journal of Cardiology</i> , 2011, 27, 159-166.	0.8	17
536	Statins in prevention and treatment of severe sepsis and septic shock. <i>European Journal of Internal Medicine</i> , 2011, 22, 125-133.	1.0	59
537	The Polypill in the prevention of cardiovascular disease. <i>Preventive Medicine</i> , 2011, 52, 16-17.	1.6	19
538	Low-density lipoprotein cholesterol and risk of coronary heart disease among Japanese men and women: The Circulatory Risk in Communities Study (CIRCS). <i>Preventive Medicine</i> , 2011, 52, 381-386.	1.6	79
539	A pilot comprehensive lifestyle intervention program (CLIP) – Comparison with qualitative lifestyle advice and simvastatin on cardiovascular risk factors in overweight hypercholesterolaemic individuals. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 165-172.	1.1	10
541	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	1.0	2,767
542	Statins for the primary prevention of cardiovascular disease. , 2011, , CD004816.		204
543	Statins therapy: a review on conventional and novel formulation approaches. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 983-998.	1.2	40
544	Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. <i>Radiotherapy and Oncology</i> , 2011, 101, 100-108.	0.3	32
545	Statins – increasing or reducing the risk of Parkinson's disease?. <i>Experimental Neurology</i> , 2011, 228, 1-4.	2.0	11
546	Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. <i>Atherosclerosis</i> , 2011, 217, 479-485.	0.4	26

#	ARTICLE	IF	CITATIONS
547	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 1-44.	0.4	180
548	ESC/EAS Guidelines for the management of dyslipidaemias. <i>Atherosclerosis</i> , 2011, 217, 3-46.	0.4	561
549	Aspirin in the prevention of cancer. <i>Lancet</i> , The, 2011, 377, 1649.	6.3	9
550	Higher Baseline LDL-C Levels Amplify the Short-Term Benefit of Early Intensive Statin Treatment in Acute Coronary Syndrome. <i>Journal of Atherosclerosis and Thrombosis</i> , 2011, 18, 42-48.	0.9	6
551	Rhabdomyolysis with simvastatin. <i>BMJ Case Reports</i> , 2011, 2011, bcr1220092552-bcr1220092552.	0.2	2
554	<i>Pharmacologie et Thérapeutique Vasculaire.</i> , 2011, , 687-843.		0
555	Genetic Variants at Newly Identified Lipid Loci Are Associated with Coronary Heart Disease in a Chinese Han Population. <i>PLoS ONE</i> , 2011, 6, e27481.	1.1	40
556	Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data. <i>BMJ: British Medical Journal</i> , 2011, 342, d12-d12.	2.4	14
557	Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 146-152.	1.0	11
558	The polypill to prevent cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2011, 26, 438-442.	0.8	9
560	Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 766-776.	1.1	32
561	Venous thromboembolism, statins and the protein unfolding response. <i>International Journal of Clinical Practice</i> , 2011, 65, 376-377.	0.8	0
562	A Population Pharmacokinetic-Pharmacodynamic Model for Simvastatin that Predicts Low-Density Lipoprotein-Cholesterol Reduction in Patients with Primary Hyperlipidaemia. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 156-163.	1.2	35
563	The Influence of Dosing Time, Variable Compliance and Circadian Low-Density Lipoprotein Production on the Effect of Simvastatin: Simulations from a Pharmacokinetic-Pharmacodynamic Model. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 494-498.	1.2	10
564	Rosuvastatin Lowers Coenzyme Q10 Levels, but not Mitochondrial Adenosine Triphosphate Synthesis, in Children with Familial Hypercholesterolemia. <i>Journal of Pediatrics</i> , 2011, 158, 458-462.	0.9	25
565	Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study. <i>Clinical Therapeutics</i> , 2011, 33, 1-12.	1.1	33
566	Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. <i>European Journal of Pharmacology</i> , 2011, 666, 135-141.	1.7	42
567	Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular disease. <i>European Journal of Pharmacology</i> , 2011, 668, S91-S100.	1.7	12

#	ARTICLE	IF	CITATIONS
568	Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 241-249.	1.9	93
569	Economic evaluation of ezetimibe combined with simvastatin for the treatment of primary hypercholesterolaemia. <i>Netherlands Heart Journal</i> , 2011, 19, 61-67.	0.3	13
570	Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). <i>Clinical Research in Cardiology</i> , 2011, 100, 277-287.	1.5	9
571	Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. <i>Heart and Vessels</i> , 2011, 26, 628-636.	0.5	13
572	Suboptimal use of statins at treatment initiation. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 971-973.	0.8	9
573	Practice variation in a longitudinal perspective: a multilevel analysis of the prescription of simvastatin in general practices between 2003 and 2009. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1205-1211.	0.8	12
574	Beyond Cholesterol in the Primary Prevention of Cardiovascular Disease: Is The Polypill the Answer?. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 38-44.	0.8	1
575	Fifty years of drug discovery from fungi. <i>Fungal Diversity</i> , 2011, 50, 3-19.	4.7	148
576	Sex-specific association of rs16996148 SNP in the NCAN/CILP2/PBX4 and serum lipid levels in the Mulao and Han populations. <i>Lipids in Health and Disease</i> , 2011, 10, 248.	1.2	18
577	Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1088-1097.	0.9	7
578	Influence of the use of functional foods enriched with phytosterols/steranols on adherence to statin therapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 830-837.	0.9	12
580	Can we dramatically reduce the incidence of coronary heart disease?. <i>Nature Reviews Cardiology</i> , 2011, 8, 721-725.	6.1	40
581	Impact of High-Dose Atorvastatin on Endothelial, Platelet, and Angiogenic Indices. <i>Angiology</i> , 2011, 62, 571-578.	0.8	11
582	Effective Lipid-lowering Therapy in High-risk Patients. <i>The European Journal of Cardiovascular Medicine</i> , 2011, 1, .	1.0	0
583	Significance of LDL-C lowering therapy in diabetic patients. <i>Clinical Lipidology</i> , 2011, 6, 389-399.	0.4	4
584	Genetic loci for blood lipid levels identified by linkage and association analyses in Caribbean Hispanics. <i>Journal of Lipid Research</i> , 2011, 52, 1411-1419.	2.0	25
585	Statin Use Associates with a Lower Incidence of Acute Kidney Injury after Major Elective Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 939-946.	3.0	105
586	Rho kinase inhibitors for treatment of glaucoma. <i>Expert Review of Ophthalmology</i> , 2011, 6, 611-622.	0.3	18

#	ARTICLE	IF	CITATIONS
587	Prospects for a Cardiovascular Disease Prevention Polypill. <i>Annual Review of Public Health</i> , 2011, 32, 23-38.	7.6	9
588	Agreement Between Fasting and Postprandial LDL Cholesterol Measured with 3 Methods in Patients with Type 2 Diabetes Mellitus. <i>Clinical Chemistry</i> , 2011, 57, 298-308.	1.5	20
589	Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1316-1325.	2.2	116
590	Primary prevention of stroke: blood pressure, lipids, and heart failure. <i>European Heart Journal</i> , 2011, 32, 545-552.	1.0	76
591	Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. <i>European Heart Journal</i> , 2012, 33, 857-865.	1.0	201
592	The Fetal Origins of the Metabolic Syndrome: Can We Intervene?. <i>Journal of Pregnancy</i> , 2012, 2012, 1-11.	1.1	14
593	Pharmacoepidemiology in the Postmarketing Assessment of the Safety and Efficacy of Drugs in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67A, 181-188.	1.7	44
594	Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience. <i>Heart Asia</i> , 2012, 4, 69-76.	1.1	4
595	ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK. <i>Heart</i> , 2012, 98, 865-871.	1.2	25
596	Evaluation of Cardiovascular Morbidity Associated with Adherence to Atorvastatin Therapy. <i>American Journal of Therapeutics</i> , 2012, 19, 24-32.	0.5	34
597	The cardiovascular polypill in high-risk patients. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 1234-1242.	0.8	23
598	Influence of Dairy Product and Milk Fat Consumption on Cardiovascular Disease Risk: A Review of the Evidence. <i>Advances in Nutrition</i> , 2012, 3, 266-285.	2.9	213
599	Associations Between Conventional Cardiovascular Risk Factors and Risk of Peripheral Artery Disease in Men. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1660.	3.8	241
600	Pravastatin and fenofibrate in combination (Pravafenix [®]) for the treatment of high-risk patients with mixed hyperlipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 565-575.	0.6	3
601	Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 781-794.	0.8	71
602	Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. <i>British Journal of Psychiatry</i> , 2012, 200, 97-106.	1.7	332
603	Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases. <i>Scientifica</i> , 2012, 2012, 1-21.	0.6	10
604	Achievement of cholesterol targets and prescribing of higher-cost statins: a cross-sectional study in general practice. <i>British Journal of General Practice</i> , 2012, 62, e815-e820.	0.7	1

#	ARTICLE	IF	CITATIONS
606	Steroidal Compounds in Commercial Parenteral Lipid Emulsions. <i>Nutrients</i> , 2012, 4, 904-921.	1.7	51
607	Estimating Heterogeneity in the Benefits of Medical Treatment Intensity. <i>Review of Economics and Statistics</i> , 2012, 94, 635-649.	2.3	13
608	Polypill (fixed-dose combination) in the prevention of cardiovascular disease: rationale and clinical data. <i>Clinical Investigation</i> , 2012, 2, 1213-1229.	0.0	2
609	Influence of Moderate, Daily Physical Activity On Body Composition and Blood Lipid Profile in Swedish Adults. <i>Journal of Physical Activity and Health</i> , 2012, 9, 867-874.	1.0	14
610	Genome-wide association study validation identifies novel loci for atherosclerotic cardiovascular disease. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1508-1514.	1.9	134
611	Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: A systematic review and meta-analysis. <i>Nephrology</i> , 2012, 17, 545-551.	0.7	30
612	Statins for people at low risk of cardiovascular disease. <i>Lancet, The</i> , 2012, 380, 1818.	6.3	5
613	Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke. <i>Human Genetics</i> , 2012, 131, 1775-1781.	1.8	13
614	Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. <i>Journal of Clinical Lipidology</i> , 2012, 6, 5-18.	0.6	229
616	Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction. <i>Chronobiology International</i> , 2012, 29, 1390-1396.	0.9	14
617	Use of Mendelian randomisation to assess potential benefit of clinical intervention. <i>BMJ, The</i> , 2012, 345, e7325-e7325.	3.0	212
618	Safety of statins: an update. <i>Therapeutic Advances in Drug Safety</i> , 2012, 3, 133-144.	1.0	82
619	Statin use after first myocardial infarction in UK men and women from 1997 to 2006: Who started and who continued treatment?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 400-408.	1.1	24
620	The effect of high-fiber rye bread enriched with nonesterified plant sterols on major serum lipids and apolipoproteins in normocholesterolemic individuals. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 575-582.	1.1	22
621	Increased toxicity when fibrates and statins are administered in combination – A metabolomics approach with rats. <i>Toxicology Letters</i> , 2012, 211, 187-200.	0.4	24
622	An introduction to systematic reviews and meta-analyses in health care. <i>Ophthalmic and Physiological Optics</i> , 2012, 32, 174-183.	1.0	22
623	Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?. <i>European Heart Journal</i> , 2012, 33, 2258-2264.	1.0	14
624	Genetics and Hypertension: Is It Time to Change My Practice?. <i>Canadian Journal of Cardiology</i> , 2012, 28, 296-304.	0.8	22

#	ARTICLE	IF	CITATIONS
625	The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 744-756.	1.1	95
626	The Burden and Management of Dyslipidemia: Practical Issues. <i>Population Health Management</i> , 2012, 15, 302-308.	0.8	7
627	Myocardial Fatty Acid Metabolism and Lipotoxicity in the Setting of Insulin Resistance. <i>Heart Failure Clinics</i> , 2012, 8, 643-661.	1.0	21
628	The Role of the Polypill in Hypertension. , 2012, , 279-294.		0
629	Lipid lowering efficacy of atorvastatin. , 2012, 12, CD008226.		66
631	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. <i>American Journal of Human Genetics</i> , 2012, 91, 823-838.	2.6	227
632	Adherence to Drugs That Prevent Cardiovascular Disease: Meta-analysis on 376,162 Patients. <i>American Journal of Medicine</i> , 2012, 125, 882-887.e1.	0.6	609
633	Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: Role of iNOS and VEGF. <i>European Journal of Pharmacology</i> , 2012, 691, 134-142.	1.7	71
634	Evidence-Based Prediction of Statin Use with Lipid-Panel Data from the National Health and Nutrition Examination Survey. <i>Value in Health</i> , 2012, 15, 32-38.	0.1	3
635	Molecular mechanisms underlying the fetal programming of adult disease. <i>Journal of Cell Communication and Signaling</i> , 2012, 6, 139-153.	1.8	41
636	Potential cardiovascular consequences of switching from atorvastatin to generic simvastatin in the Netherlands. <i>Netherlands Heart Journal</i> , 2012, 20, 197-201.	0.3	7
637	Validation of a short food frequency questionnaire to evaluate nutritional lifestyles in hypercholesterolemic patients. <i>Annales D'Endocrinologie</i> , 2012, 73, 523-529.	0.6	13
638	Trends and risk factors of hypercholesterolemia among Kuwaiti adults: National Nutrition Surveillance Data from 1998 to 2009. <i>Nutrition</i> , 2012, 28, 917-923.	1.1	9
639	Changes to the Statin Prescribing Policy in Belgium. <i>American Journal of Cardiovascular Drugs</i> , 2012, 12, 225-232.	1.0	5
640	A Polypill for All? Critical Review of the Polypill Literature for Primary Prevention of Cardiovascular Disease and Stroke. <i>Annals of Pharmacotherapy</i> , 2012, 46, 688-695.	0.9	32
641	Randomized Polypill Crossover Trial in People Aged 50 and Over. <i>PLoS ONE</i> , 2012, 7, e41297.	1.1	128
643	Social Agents and Genes. , 0, , 117-137.		0
644	Challenge of Surrogate Endpoints. <i>Southern Medical Journal</i> , 2012, 105, 156-160.	0.3	4

#	ARTICLE	IF	CITATIONS
645	Mixed dyslipidemias in primary care patients in France. <i>Vascular Health and Risk Management</i> , 2012, 8, 247.	1.0	14
646	Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 135.	0.7	8
647	Cholesterol Level Goal Attainment with Statins: Clinical Management Guideline Recommendations versus Management in Actual Clinical Practice. <i>Pharmacotherapy</i> , 2012, 32, 631-641.	1.2	13
648	Effect of Perioperative Statins on Death, Myocardial Infarction, Atrial Fibrillation, and Length of Stay. <i>Archives of Surgery</i> , 2012, 147, 181.	2.3	104
649	Lp-PLA2: Inflammatory Biomarker of Vascular Risk in Multiple Sclerosis. <i>Journal of Clinical Immunology</i> , 2012, 32, 497-504.	2.0	16
650	Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 58-64.	0.7	18
652	Statins in Abdominal Surgery: A Systematic Review. <i>Journal of the American College of Surgeons</i> , 2012, 214, 356-366.	0.2	8
653	Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 166-172.	0.7	14
654	Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. <i>Journal of Evaluation in Clinical Practice</i> , 2012, 18, 612-615.	0.9	8
655	Earlier translation of evidence into public subsidy may prevent morbidity and mortality: an example using statins in diabetics with normal cholesterol levels. <i>Australian and New Zealand Journal of Public Health</i> , 2012, 36, 435-440.	0.8	2
656	Why Physicians Favored Lipitor Over Simvastatin. <i>JAMA Internal Medicine</i> , 2013, 173, 1473.	2.6	0
657	Association of the apolipoprotein M gene polymorphisms and serum lipid levels. <i>Molecular Biology Reports</i> , 2013, 40, 1843-1853.	1.0	9
658	Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1199-1204.	1.0	9
659	Statin Toxicity From Macrolide Antibiotic Coprescription. <i>Annals of Internal Medicine</i> , 2013, 158, 869.	2.0	132
660	Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: a systematic review. <i>BMC Public Health</i> , 2013, 13, 285.	1.2	51
661	Benefitâ€“risk assessment of plant sterols in margarine: A QALIBRA case study. <i>Food and Chemical Toxicology</i> , 2013, 54, 35-42.	1.8	8
662	Assessment of lipid-lowering treatment in Bulgaria â€” The CEPHEUS study. <i>Open Medicine (Poland)</i> , 2013, 8, 627-637.	0.6	1
663	LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?. <i>Drugs</i> , 2013, 73, 293-301.	4.9	20

#	ARTICLE	IF	CITATIONS
664	Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. <i>International Journal of Cardiology</i> , 2013, 170, 30-35.	0.8	29
665	Lipid-Lowering Agents and Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2013, 17, 699-714.	1.0	24
666	Inhibitory effect of atorvastatin on AGE-induced HCAEC apoptosis by upregulating HSF-1 protein. <i>International Journal of Biological Macromolecules</i> , 2013, 57, 259-264.	3.6	14
667	Cholesterol-Lowering Efficacy of Plant Sterols/Stanoles Provided in Capsule and Tablet Formats: Results of a Systematic Review and Meta-Analysis. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2013, 113, 1494-1503.	0.4	76
668	The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors. <i>Pharmacological Research</i> , 2013, 73, 27-34.	3.1	17
669	Molecular Biology of Atherosclerosis. <i>Physiological Reviews</i> , 2013, 93, 1317-1542.	13.1	418
670	Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 658-670.	0.8	58
671	Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 641-657.	0.8	170
672	Evaluation of the impact of the recent controversy over statins in France: The EVANS study. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 511-516.	0.7	22
673	Cardiovascular disease risk reduction in rural China: a clustered randomized controlled trial in Zhejiang. <i>Trials</i> , 2013, 14, 354.	0.7	16
674	Economic Evaluation of Cardio inCode [®] , a Clinical-Genetic Function for Coronary Heart Disease Risk Assessment. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 531-542.	1.0	12
675	Low-Density Lipoprotein Cholesterol: How Low Can We Go?. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 225-232.	1.0	10
676	Progress and Future Aspects in Genetics of Human Hypertension. <i>Current Hypertension Reports</i> , 2013, 15, 676-686.	1.5	20
677	Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 918.	3.8	330
678	Cardiovascular Risk Factor Control and Adherence to Recommended Lifestyle and Medical Therapies in Persons With Coronary Heart Disease (from the National Health and Nutrition Examination Survey) <i>Tj ETQq0 0 0 rg67/Overlook 10 Tf 50</i>	0.7	14
679	Anti-PCSK9 therapies for the treatment of hypercholesterolemia. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 429-435.	1.4	45
681	Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. <i>International Journal of Cardiology</i> , 2013, 166, 431-439.	0.8	31
682	Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. <i>Atherosclerosis</i> , 2013, 231, 411-420.	0.4	14

#	ARTICLE	IF	CITATIONS
683	Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. <i>Atherosclerosis</i> , 2013, 227, 367-372.	0.4	45
684	Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: A post hoc analysis of MEGA study. <i>Diabetes Research and Clinical Practice</i> , 2013, 100, e31-e33.	1.1	4
685	Effects of the simultaneous use of drug-eluting stents and statins in an atherosclerotic animal model. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2013, 25, 16-24.	0.4	0
686	Effect of red mold rice on blood coagulation and anticoagulation factors in a rat model of hyperlipidemia. <i>Journal of Functional Foods</i> , 2013, 5, 1956-1965.	1.6	6
687	Pilot study to validate a computer-based clinical decision support system for dyslipidemia treatment (HTE-DLP). <i>Atherosclerosis</i> , 2013, 231, 401-404.	0.4	38
688	Nondaily Statin Dosing: Mechanisms of a Potentially Important Approach to Dealing With Statin Intolerance. <i>Canadian Journal of Cardiology</i> , 2013, 29, 895-898.	0.8	2
689	Designing and implementing a comparative effectiveness study of two strategies for delivering high quality CHD prevention: Methods and participant characteristics for the Heart to Health study. <i>Contemporary Clinical Trials</i> , 2013, 36, 394-405.	0.8	16
690	Slovak Trial on Cardiovascular Risk Reduction Following National Guidelines with CaDUETÁ® (The Tj ETQq1 1 0.784314 rgBT/Overload	1.3	6
691	Proteomic analysis of endothelial cell secretome: A means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors. <i>Journal of Proteomics</i> , 2013, 78, 346-361.	1.2	37
693	Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. <i>BMJ, The</i> , 2013, 346, f880-f880.	3.0	209
694	Statins in acute kidney injury: friend or foe?. <i>BMJ, The</i> , 2013, 346, f1531-f1531.	3.0	10
695	Statins for the primary prevention of cardiovascular disease. <i>The Cochrane Library</i> , 2021, 2021, CD004816.	1.5	933
696	Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. <i>Thrombosis and Haemostasis</i> , 2013, 110, 366-377.	1.8	104
697	Bilirubin and beyond: A review of lipid status in Gilbertâ€™s syndrome and its relevance to cardiovascular disease protection. <i>Progress in Lipid Research</i> , 2013, 52, 193-205.	5.3	105
698	Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care. <i>Current Medical Research and Opinion</i> , 2013, 29, 751-760.	0.9	6
699	Risk of incident diabetes among patients treated with statins: population based study. <i>BMJ, The</i> , 2013, 346, f2610-f2610.	3.0	338
700	Lipid effects of a dietary supplement softgel capsule containing plant sterols/stanols in primary hypercholesterolemia. <i>Nutrition</i> , 2013, 29, 96-100.	1.1	32
701	Statin treatment and the risk of recurrent pulmonary embolism. <i>European Heart Journal</i> , 2013, 34, 1800-1806.	1.0	83

#	ARTICLE	IF	CITATIONS
702	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2013, 7, 561-565.	0.6	147
704	Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study: Table A1. <i>BMJ Open</i> , 2013, 3, e002498.	0.8	25
705	Exploring causal associations between alcohol and coronary heart disease risk factors: findings from a Mendelian randomization study in the Copenhagen General Population Study. <i>European Heart Journal</i> , 2013, 34, 2519-2528.	1.0	81
706	Low-density lipoprotein subfraction, carotid artery intima-media thickness, nitric oxide, and tumor necrosis factor alpha are associated with newly diagnosed ischemic stroke. <i>Annals of Indian Academy of Neurology</i> , 2013, 16, 498.	0.2	28
707	Association of the KLF14 rs4731702 SNP and Serum Lipid Levels in the Guangxi Mulao and Han Populations. <i>BioMed Research International</i> , 2013, 2013, 1-13.	0.9	18
708	Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 299-306.	0.2	30
709	The Effect of Sodium Tanshinone IIA Sulfate and Simvastatin on Elevated Serum Levels of Inflammatory Markers in Patients with Coronary Heart Disease: A Study Protocol for a Randomized Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013, 2013, 1-8.	0.5	28
710	The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1135.	2.0	40
711	Reappraisal of SFA and cardiovascular risk. <i>Proceedings of the Nutrition Society</i> , 2013, 72, 390-398.	0.4	17
712	Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. <i>The Cochrane Library</i> , 2014, 2014, CD009971.	1.5	50
713	“When Diet and Exercise Are Not Enough”: An Examination of Lifestyle Change Inefficacy Claims in Direct-to-Consumer Advertising. <i>Health Communication</i> , 2013, 28, 800-813.	1.8	12
714	Differential Effect of Everolimus on Progression of Early and Late Cardiac Allograft Vasculopathy in Current Clinical Practice. <i>American Journal of Transplantation</i> , 2013, 13, 1217-1226.	2.6	62
715	Endocrine, Lifestyle, and Genetic Factors in the Development of Metabolic Syndrome. <i>Arhiv Za Higijenu Rada I Toksikologiju</i> , 2013, 64, 581-591.	0.4	5
716	Improved Cardiovascular Risk Prediction Using Nonparametric Regression and Electronic Health Record Data. <i>Medical Care</i> , 2013, 51, 251-258.	1.1	52
717	Lipid-lowering treatment in patients at high cardiovascular risk discharged from an Italian hospital. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 270-275.	0.6	1
718	Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. <i>Vascular Health and Risk Management</i> , 2013, 9, 671.	1.0	28
719	Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry. <i>Vascular Health and Risk Management</i> , 2013, 9, 71.	1.0	7
720	Small Dense Low-Density Lipoproteins Cholesterol can Predict Incident Cardiovascular Disease in an Urban Japanese Cohort: The Suita Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 195-203.	0.9	103

#	ARTICLE	IF	CITATIONS
721	Construction of a three-dimensional model of cardiovascular disease and deployment of a new method of fostering patient adherence to instruction. <i>Patient Preference and Adherence</i> , 2013, 7, 579.	0.8	0
722	A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 55.	1.0	14
723	Statin Use and Markers of Immunity in the Doetinchem Cohort Study. <i>PLoS ONE</i> , 2013, 8, e77587.	1.1	8
724	Plant Sterols as Anticancer Nutrients: Evidence for Their Role in Breast Cancer. <i>Nutrients</i> , 2013, 5, 359-387.	1.7	98
725	Effects of Pravastatin and Atorvastatin on HDL Cholesterol and Glucose Metabolism in Patients with Dyslipidemia and Glucose Intolerance: The PRAT Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2013, 20, 368-379.	0.9	14
726	Lipid composition of medicinal plants: <i>Portulaca oleracea</i> and <i>Ficus thonningi</i> . <i>African Journal of Food Science</i> , 2013, 7, 76-79.	0.4	2
727	Efficacy of Standard and Intensive Statin Treatment for the Secondary Prevention of Cardiovascular and Cerebrovascular Events in Diabetes Patients: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e111247.	1.1	42
728	High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma. <i>PLoS ONE</i> , 2014, 9, e90602.	1.1	15
729	The Complementary Effects of Atorvastatin and Exercise Treatment on the Composition and Stability of the Atherosclerotic Plaques in ApoE Knockout Mice. <i>PLoS ONE</i> , 2014, 9, e108240.	1.1	23
730	Examination of the FDA Warning for Statins and Cognitive Dysfunction. <i>Journal of Pharmacovigilance</i> , 2014, 02, .	0.2	15
731	Relationship Between Statin Type and Responsiveness to Clopidogrel in Patients Treated with Percutaneous Coronary Intervention: A Subgroup Analysis of the CILON-T Trial. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 140-150.	0.9	12
732	Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. <i>Vascular Health and Risk Management</i> , 2014, 10, 89.	1.0	32
733	Geospatial Analysis of Statin Adherence Using Pharmacy Claims Data in the State of Michigan. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 1208-1215.	2.2	11
734	Author's reply to Phillips and Brugts. <i>BMJ</i> , The, 2014, 349, g4890-g4890.	3.0	0
735	Cerebrovascular Diseases. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 175-179.	0.9	1
737	Retrospective case review of missed opportunities for primary prevention of stroke and TIA in primary care: protocol paper. <i>BMJ Open</i> , 2014, 4, e006622.	0.8	3
738	Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS Study in Egypt. <i>Cardiology and Therapy</i> , 2014, 3, 27-40.	1.1	9
739	Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example. <i>European Journal of Epidemiology</i> , 2014, 29, 605-612.	2.5	19

#	ARTICLE	IF	CITATIONS
740	Does use of pooled cohort risk score overestimate the use of statin?: a retrospective cohort study in a primary care setting. <i>BMC Family Practice</i> , 2014, 15, 172.	2.9	6
741	LDL cholesterol: should guidelines include targets?. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 285-290.	0.6	1
742	Functional ingredients and cardiovascular protective effect of pumpkin seed oils. <i>Grasas Y Aceites</i> , 2014, 65, e007.	0.3	7
743	Alternate Day versus Once Daily Atorvastatin for Primary Prevention of (CHD) in Na ⁺ ve Patients of Dyslipidemia. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2014, 8, 27-31.	0.8	6
744	Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial. <i>Mediators of Inflammation</i> , 2014, 2014, 1-10.	1.4	23
745	Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. <i>Neurosurgical Focus</i> , 2014, 36, E10.	1.0	2
746	Natural cholesterol-lowering products: focus on probiotics. <i>British Journal of Community Nursing</i> , 2014, 19, S14-S18.	0.2	10
747	Association Between Persistence with Statin Therapy and Reduction in Low-Density Lipoprotein Cholesterol Level: Analysis of Real-Life Data from Community Settings. <i>Pharmacotherapy</i> , 2014, 34, 1-8.	1.2	21
748	Optimising the Detection and Management of Familial Hypercholesterolaemia: Central Role of Primary Care and its Integration with Specialist Services. <i>Heart Lung and Circulation</i> , 2014, 23, 1158-1164.	0.2	49
749	Pharmacogenomics in the Development and Characterization of Atheroprotective Drugs. <i>Methods in Molecular Biology</i> , 2014, 1175, 259-300.	0.4	5
750	Simvastatin Exerts Antiamnesic Effect in β -Secretase 1 Injected Mice. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 218-226.	1.9	23
751	Safe use of statins in elderly people. <i>Journal of Pharmacy Practice and Research</i> , 2014, 44, 138-142.	0.5	4
752	Differences in Lipid Profiles in Two Hispanic Ischemic Stroke Populations. <i>International Journal of Stroke</i> , 2014, 9, 394-399.	2.9	5
753	Geographic Variation in Statin Use for Complex Acute Myocardial Infarction Patients. <i>Medical Care</i> , 2014, 52, S37-S44.	1.1	22
754	Evidence of Sample Use Among New Users of Statins. <i>Medical Care</i> , 2014, 52, 773-780.	1.1	33
755	The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy. <i>Current Opinion in Lipidology</i> , 2014, 25, 239-246.	1.2	12
756	Causal Inference Using Mixture Models. <i>Medical Care</i> , 2014, 52, 770-772.	1.1	1
757	Effect of Collaborative Care for Depression on Risk of Cardiovascular Events. <i>Psychosomatic Medicine</i> , 2014, 76, 29-37.	1.3	98

#	ARTICLE	IF	CITATIONS
758	Statin Therapy Is Associated with Improved Survival in Patients with Non-Serous-Papillary Epithelial Ovarian Cancer: A Retrospective Cohort Analysis. <i>PLoS ONE</i> , 2014, 9, e104521.	1.1	39
759	Genetic architecture of lipid traits changes over time and differs by race: Princeton Lipid Follow-up Study. <i>Journal of Lipid Research</i> , 2014, 55, 1515-1524.	2.0	11
760	Death, Debility, and Destitution Following Hip Fracture. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69A, 346-353.	1.7	125
761	Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia. <i>Angiology</i> , 2014, 65, 919-926.	0.8	27
762	LDL-C Levels in US Patients at High Cardiovascular Risk Receiving Rosuvastatin Monotherapy. <i>Clinical Therapeutics</i> , 2014, 36, 792-799.	1.1	3
763	High-potency statins increase the risk of acute kidney injury: Evidence from a large population-based study. <i>Atherosclerosis</i> , 2014, 234, 224-229.	0.4	19
764	The "New Deadly Quartet" for Cardiovascular Disease in the 21st Century: Obesity, Metabolic Syndrome, Inflammation and Climate Change: How Does Statin Therapy Fit into this Equation?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 380.	2.0	19
765	An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. <i>Journal of Clinical Lipidology</i> , 2014, 8, 29-60.	0.6	289
767	Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor. <i>Archives of Biochemistry and Biophysics</i> , 2014, 545, 124-132.	1.4	14
768	Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. <i>Journal of Internal Medicine</i> , 2014, 276, 396-403.	2.7	57
769	Periodontal Status Affects C-reactive Protein and Lipids in Patients With Stable Heart Disease From a Tertiary Care Cardiovascular Clinic. <i>Journal of Periodontology</i> , 2014, 85, 545-553.	1.7	22
770	Determination of statins by gas chromatography " EI/MS/MS " Tandem mass spectrometry: Fermentation of pine samples with <i>Pleurotus ostreatus</i> . <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 94, 196-202.	1.4	14
771	Targeting LDL: Is lower better and is it safe?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2014, 28, 309-324.	2.2	27
772	Dose-Related Effects of Statins on Symptomatic Intracerebral Hemorrhage and Outcome After Thrombolysis for Ischemic Stroke. <i>Stroke</i> , 2014, 45, 509-514.	1.0	70
773	Target-Attainment Rates of Low-Density Lipoprotein Cholesterol Using Lipid-Lowering Drugs One Year After Acute Myocardial Infarction in Sweden. <i>American Journal of Cardiology</i> , 2014, 113, 17-22.	0.7	10
774	Statins and the Risk of Herpes Zoster: A Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 350-356.	2.9	45
775	Rosuvastatin for lowering lipids. <i>The Cochrane Library</i> , 2017, 2017, CD010254.	1.5	41
776	Cost-Effectiveness Analysis of Atorvastatin versus Rosuvastatin in Primary and Secondary Cardiovascular Prevention Populations in Brazil and Columbia. <i>Value in Health Regional Issues</i> , 2014, 5, 48-57.	0.5	7

#	ARTICLE	IF	CITATIONS
777	Comparative effectiveness of rosuvastatin versus simvastatin in primary prevention among new users: a cohort study in the French national health insurance database. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 240-250.	0.9	24
778	Mechanisms and assessment of statin-related muscular adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 454-466.	1.1	88
779	Taking a longer term view of cardiovascular risk: the causal exposure paradigm. <i>BMJ, The</i> , 2014, 348, g3047-g3047.	3.0	23
780	TRIB1 downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions. <i>Journal of Molecular Endocrinology</i> , 2014, 52, 145-158.	1.1	49
781	Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. <i>Vascular Pharmacology</i> , 2014, 63, 79-87.	1.0	49
782	Optimization of Rutaecarpine as ABCA1 Up-Regulator for Treating Atherosclerosis. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 884-888.	1.3	30
783	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. <i>Journal of Clinical Lipidology</i> , 2014, 8, 594-605.	0.6	11
784	Association of rheumatoid arthritis susceptibility gene with lipid profiles in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2014, 53, 1014-1021.	0.9	16
785	Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. <i>Internal Medicine Journal</i> , 2014, 44, 690-693.	0.5	23
786	Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. <i>BMJ, The</i> , 2014, 349, g4356-g4356.	3.0	236
787	Clinical- and cost-effectiveness of LDL particle-guided statin therapy: A simulation study. <i>Atherosclerosis</i> , 2014, 236, 154-161.	0.4	15
788	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial. <i>International Journal of Cardiology</i> , 2014, 176, 55-61.	0.8	229
789	Increased levels of small dense low-density lipoprotein cholesterol associated with hemorheological abnormalities in untreated, early-stage essential hypertensives. <i>Hypertension Research</i> , 2014, 37, 1008-1013.	1.5	15
790	Associations between APOE and low-density lipoprotein cholesterol genotypes and cognitive and physical capability: the HALCYon programme. <i>Age</i> , 2014, 36, 9673.	3.0	23
791	Graft Vessel Disease Following Heart Transplantation: A Systematic Review of the Role of Statin Therapy. <i>World Journal of Surgery</i> , 2014, 38, 2324-2334.	0.8	9
792	No impact of SLC01B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. <i>Molecular Biology Reports</i> , 2014, 41, 4631-4638.	1.0	22
793	The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 383-389.	0.7	16
794	Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. <i>BMJ, The</i> , 2014, 348, g3244-g3244.	3.0	142

#	ARTICLE	IF	CITATIONS
795	Influence of SREBP-2 and SCAP Gene Polymorphisms on Lipid-Lowering Response to Atorvastatin in a Cohort of Chilean Subjects with Amerindian Background. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 435-443.	1.6	12
796	Socioeconomic position across the lifecourse & allostatic load: data from the West of Scotland Twenty-07 cohort study. <i>BMC Public Health</i> , 2014, 14, 184.	1.2	50
797	Primary prevention for risk factors of ischemic stroke with Baduanjin exercise intervention in the community elder population: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 113.	0.7	25
798	Simplifying the medical prevention of cardiovascular disease. <i>Medicine</i> , 2014, 42, 491-494.	0.2	0
799	Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study. <i>Diabetes Care</i> , 2014, 37, 2225-2232.	4.3	83
800	Lipids in health and disease. <i>Nature</i> , 2014, 510, 47-47.	13.7	24
801	Statin treatment and new-onset diabetes: A review of proposed mechanisms. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 735-745.	1.5	186
802	Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. <i>Journal of Clinical Lipidology</i> , 2014, 8, 61-68.	0.6	74
804	Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: Can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. <i>Atherosclerosis</i> , 2014, 234, 136-141.	0.4	51
805	A Softgel Dietary Supplement Containing Esterified Plant Sterols and Stanols Improves the Blood Lipid Profile of Adults with Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Replication Study. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2014, 114, 244-249.	0.4	15
806	Are investments in disease prevention complements? The case of statins and health behaviors. <i>Journal of Health Economics</i> , 2014, 36, 151-163.	1.3	27
807	Statins: Can we advocate them for primary prevention of heart disease?. <i>Medical Journal Armed Forces India</i> , 2014, 70, 270-273.	0.3	8
808	The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis. <i>Current Medical Research and Opinion</i> , 2014, 30, 1777-1786.	0.9	14
809	Future of Polypill Use for the Prevention of Cardiovascular Disease and Strokes. <i>American Journal of Cardiology</i> , 2014, 114, 641-645.	0.7	13
810	Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes. <i>Annals of Internal Medicine</i> , 2014, 161, 400.	2.0	137
811	Phosphodiesterase 3A rs7134375 single nucleotide polymorphism and serum lipid levels. <i>Molecular Medicine Reports</i> , 2014, 9, 1618-1628.	1.1	4
812	Cost-Effectiveness of High, Moderate and Low-Dose Statins in the Prevention of Vascular Events in the Brazilian Public Health System. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 104, 32-44.	0.3	16
813	Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data. <i>BMJ, The</i> , 2014, 349, g5293-g5293.	3.0	106

#	ARTICLE	IF	CITATIONS
814	Genetic variation in the <i>UGT1A</i> locus is associated with simvastatin efficacy in a clinical practice setting. <i>Pharmacogenomics</i> , 2014, 15, 1739-1747.	0.6	6
815	How effective are common medications: a perspective based on meta-analyses of major drugs. <i>BMC Medicine</i> , 2015, 13, 253.	2.3	77
816	Statins Provide Less Benefit in Populations with High Noncardiovascular Mortality Risk: Meta-Regression of Randomized Controlled Trials. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1413-1419.	1.3	5
817	The influence of a ten-week Nordic walking training-rehabilitation program on the level of lipids in blood in overweight and obese postmenopausal women. <i>Journal of Physical Therapy Science</i> , 2015, 27, 3039-3044.	0.2	7
818	The role of TRIB1 in lipid metabolism; from genetics to pathways. <i>Biochemical Society Transactions</i> , 2015, 43, 1063-1068.	1.6	17
819	A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention: Table A1. <i>Evidence-Based Medicine</i> , 2015, 20, 162-169.	0.6	7
820	Targeted study to evaluate the cardiovascular risk factor status among patients and efficacy of statins in attaining goal lipid levels in a regional hospital in Sultanate of Oman. <i>Saudi Pharmaceutical Journal</i> , 2015, 23, 371-376.	1.2	1
821	The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. <i>Lipids in Health and Disease</i> , 2015, 14, 127.	1.2	22
822	The importance of age, sex and place in understanding socioeconomic inequalities in allostatic load: Evidence from the Scottish Health Survey (2008-2011). <i>BMC Public Health</i> , 2015, 16, 126.	1.2	20
823	How low should we target the LDL goal to improve survival for acute coronary syndrome patients in Hong Kong?. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 117.	0.7	11
824	Genetic variants of numb gene were associated with elevated total cholesterol level and low density lipoprotein cholesterol level in Chinese subjects, in Xinjiang, China. <i>Diagnostic Pathology</i> , 2015, 10, 141.	0.9	3
825	NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins. <i>Coronary Artery Disease</i> , 2015, 26, 409-421.	0.3	58
826	Common statin side effects explain poor compliance. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 170-171.	1.1	4
827	Excessive range of statin dose in Western Australian primary care. <i>Internal Medicine Journal</i> , 2015, 45, 860-863.	0.5	3
828	Prioritizing health outcomes in a limited world. <i>Current Opinion in Lipidology</i> , 2015, 26, 188-194.	1.2	2
829	State of the art paper Improvement of hepatic bioavailability as a new step for the future of statin. <i>Archives of Medical Science</i> , 2015, 2, 406-410.	0.4	32
830	Relation of Cholesterol Level to Dietary Fat Intake in Patients of Ischemic Heart Disease. <i>Cardiovascular Pharmacology: Open Access</i> , 2015, 04, .	0.1	2
831	Sitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia – a review of its characteristics. <i>Vascular Health and Risk Management</i> , 2015, 11, 125.	1.0	17

#	ARTICLE	IF	CITATIONS
832	Inter-Ethnic Differences in Quantified Coronary Artery Disease Severity and All-Cause Mortality among Dutch and Singaporean Percutaneous Coronary Intervention Patients. <i>PLoS ONE</i> , 2015, 10, e0131977.	1.1	13
833	Meta-Analysis: Effects of Probiotic Supplementation on Lipid Profiles in Normal to Mildly Hypercholesterolemic Individuals. <i>PLoS ONE</i> , 2015, 10, e0139795.	1.1	128
834	Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy. <i>International Journal of Nanomedicine</i> , 2015, 10, 321.	3.3	45
835	Reaction Time in Adolescence, Cumulative Allostatic Load, and Symptoms of Anxiety and Depression in Adulthood. <i>Psychosomatic Medicine</i> , 2015, 77, 493-505.	1.3	13
836	Atorvastatin for lowering lipids. <i>The Cochrane Library</i> , 2017, 2017, CD008226.	1.5	66
837	Data mining for censored time-to-event data: a Bayesian network model for predicting cardiovascular risk from electronic health record data. <i>Data Mining and Knowledge Discovery</i> , 2015, 29, 1033-1069.	2.4	65
838	Acute and chronic impact of cardiovascular events on health state utilities. <i>BMC Health Services Research</i> , 2015, 15, 173.	0.9	47
839	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. <i>Atherosclerosis</i> , 2015, 241, 169-175.	0.4	133
840	The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. <i>International Journal of Cardiology</i> , 2015, 201, S15-S23.	0.8	32
841	Using a Systems Pharmacology Approach to Study the Effect of Statins on the Early Stage of Atherosclerosis in Humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 41-50.	1.3	8
842	Patients'™ views about taking a polypill to manage cardiovascular risk: a qualitative study in primary care. <i>British Journal of General Practice</i> , 2015, 65, e447-e453.	0.7	14
843	Effects of Zinc supplementation on serum lipids: a systematic review and meta-analysis. <i>Nutrition and Metabolism</i> , 2015, 12, 26.	1.3	137
844	Evaluation of a systematic cardiovascular disease risk reduction strategy in primary healthcare: an exploratory study from Zhejiang, China. <i>Journal of Public Health</i> , 2015, 37, 241-250.	1.0	10
845	Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 541-551.	0.9	24
846	Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease". <i>Circulation</i> , 2015, 132, e203.	1.6	2
847	Statin Dose Based on Limited Evidence. <i>Journal of the American College of Cardiology</i> , 2015, 65, 759-760.	1.2	8
848	Myocardial Adaptations to Recreational Marathon Training Among Middle-Aged Men. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, e002487.	1.3	55
849	Subsequent Vascular Events after Ischemic Stroke: The Japan Statin Treatment against Recurrent Stroke"™ Longitudinal. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 473-479.	0.7	6

#	ARTICLE	IF	CITATIONS
850	Studies on urea co-inclusion complexes of simvastatin for improvement of pharmaceutical characteristics. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2015, 81, 105-120.	0.9	13
851	On the hypothetical universal use of statins in primary prevention: an observational analysis on low-risk patients and economic consequences of a potential wide prescription rate. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 449-459.	0.8	1
852	Drug-drug interactions that interfere with statin metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1435-1447.	1.5	63
853	Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment. <i>European Heart Journal</i> , 2015, 36, ehv340.	1.0	71
854	Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT). <i>Atherosclerosis</i> , 2015, 238, 336-343.	0.4	83
855	Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. <i>Atherosclerosis</i> , 2015, 241, 641-648.	0.4	16
856	A Pharmacometabonomic Approach To Predicting Metabolic Phenotypes and Pharmacokinetic Parameters of Atorvastatin in Healthy Volunteers. <i>Journal of Proteome Research</i> , 2015, 14, 3970-3981.	1.8	36
857	Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic. <i>Angiology</i> , 2015, 66, 346-353.	0.8	27
858	Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS). <i>Clinical and Experimental Hypertension</i> , 2015, 37, 116-121.	0.5	5
859	A comparative study on the cardioprotective potential of atorvastatin and simvastatin in hyperhomocysteinemic rat hearts. <i>European Journal of Pharmacology</i> , 2015, 764, 48-54.	1.7	9
860	LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?. <i>Current Cardiology Reports</i> , 2015, 17, 610.	1.3	11
861	Living in an urban environment and non-communicable disease risk in Thailand: Does timing matter?. <i>Health and Place</i> , 2015, 33, 37-47.	1.5	6
862	Target organ damage and control of cardiovascular risk factors in hypertensive patients. <i>Herz</i> , 2015, 40, 209-216.	0.4	7
863	The Promise of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors for the Treatment of Familial Hypercholesterolemia. <i>Current Atherosclerosis Reports</i> , 2015, 17, 508.	2.0	0
864	Integrated Preclinical Cardiovascular Prevention: A New Paradigm to Face Growing Challenges of Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 163-170.	1.0	6
866	The Effect of Cardiorespiratory Fitness on Age-Related Lipids and Lipoproteins. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2091-2100.	1.2	77
867	The Burden of Non-Adherence to Cardiovascular Medications Among the Aging Population in Australia: A Meta-Analysis. <i>Drugs and Aging</i> , 2015, 32, 217-225.	1.3	24
868	Lower cardiovascular mortality with atorvastatin and rosuvastatin vs simvastatin: Data from moderate-intensity statin users in an observational registry on chronic heart failure (Daunia Heart) Tj ETQq1d.0.784334 rgBT /Dv		

#	ARTICLE	IF	CITATIONS
869	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€”Full Report. <i>Journal of Clinical Lipidology</i> , 2015, 9, 129-169.	0.6	632
870	Statin Use After Acute Myocardial Infarction by Patient Complexity. <i>Medical Care</i> , 2015, 53, 324-331.	1.1	11
871	The role of material, psychosocial and behavioral factors in mediating the association between socioeconomic position and allostatic load (measured by cardiovascular, metabolic and inflammatory) Tj ETQqO O QzrgBT /Overclock 10 T		
872	Sources for Leads: Natural Products and Libraries. <i>Handbook of Experimental Pharmacology</i> , 2015, 232, 91-123.	0.9	7
873	3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. <i>Journal of Controlled Release</i> , 2015, 217, 308-314.	4.8	446
874	The Danish fat taxâ€”Effects on consumption patterns and risk of ischaemic heart disease. <i>Preventive Medicine</i> , 2015, 77, 200-203.	1.6	31
875	Next Steps in Primary Prevention of Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1828-1836.	1.2	50
876	Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients. <i>Current Medical Research and Opinion</i> , 2015, 31, 2197-2206.	0.9	8
877	Cardiovascular risk assessment and lipid modification: NICE guideline. <i>British Journal of General Practice</i> , 2015, 65, 378-380.	0.7	42
878	A comparative study of four independent methods to measure LDL particle concentration. <i>Atherosclerosis</i> , 2015, 243, 99-106.	0.4	14
879	Antilipidemic Drug Therapy Today and in the Future. <i>Handbook of Experimental Pharmacology</i> , 2015, 233, 373-435.	0.9	5
880	The Effects of Publicity on Demand: The Case of Anti-Cholesterol Drugs. <i>Marketing Science</i> , 2016, 35, 158-181.	2.7	38
881	Toxicokinetics and toxicity of atorvastatin in dogs. <i>Toxicology and Applied Pharmacology</i> , 2015, 289, 117-123.	1.3	13
883	Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: A systematic review from sham CPAP randomized controlled trials. <i>Sleep Medicine Reviews</i> , 2015, 21, 23-38.	3.8	155
884	Overview of guidelines for the management of dyslipidemia: EU perspectives. <i>Vascular Health and Risk Management</i> , 2016, Volume 12, 357-369.	1.0	16
885	Rosuvastatin Reduces Blood Viscosity in Patients with Acute Coronary Syndrome. <i>Korean Circulation Journal</i> , 2016, 46, 147.	0.7	12
886	Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). <i>Journal of Atherosclerosis and Thrombosis</i> , 2016, 23, 567-587.	0.9	52
887	Prompt impact of first prospective statin mega-trials on postoperative lipid management of CABG patients: a 20-year follow-up in a single hospital. <i>Lipids in Health and Disease</i> , 2016, 15, 124.	1.2	3

#	ARTICLE	IF	CITATIONS
888	Association of KCTD10, MVK, and MMAB polymorphisms with dyslipidemia and coronary heart disease in Han Chinese population. <i>Lipids in Health and Disease</i> , 2016, 15, 171.	1.2	18
889	Financial Burden and Impoverishment Due to Cardiovascular Medications in Low and Middle Income Countries: An Illustration from India. <i>PLoS ONE</i> , 2016, 11, e0155293.	1.1	8
890	Physiological Adjustments and Circulating MicroRNA Reprogramming Are Involved in Early Acclimatization to High Altitude in Chinese Han Males. <i>Frontiers in Physiology</i> , 2016, 7, 601.	1.3	11
891	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. <i>World Journal of Cardiology</i> , 2016, 8, 201.	0.5	47
892	Statin use and the risk of herpes zoster: a nested case-control study using primary care data from the U.K. <i>Clinical Research Practice Datalink. British Journal of Dermatology</i> , 2016, 175, 1183-1194.	1.4	19
893	The Effect of Atorvastatin on Habitual Physical Activity among Healthy Adults. <i>Medicine and Science in Sports and Exercise</i> , 2016, 48, 1-6.	0.2	12
894	Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson disease. <i>Synapse</i> , 2016, 70, 231-239.	0.6	11
895	Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study. <i>International Journal of Clinical Practice</i> , 2016, 70, 482-492.	0.8	8
896	Statins in prevention and treatment of ischemic stroke. <i>Human Physiology</i> , 2016, 42, 858-864.	0.1	0
897	An update on the relationship between statins and physical activity. <i>Current Opinion in Cardiology</i> , 2016, 31, 572-579.	0.8	7
898	Fluvastatin for lowering lipids. <i>The Cochrane Library</i> , 2016, , .	1.5	4
899	Children with hypercholesterolemia of unknown cause: Value of genetic risk scores. <i>Journal of Clinical Lipidology</i> , 2016, 10, 851-859.	0.6	21
900	Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke. <i>European Journal of Epidemiology</i> , 2016, 31, 415-426.	2.5	22
901	Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. <i>Clinical Research in Cardiology</i> , 2016, 105, 783-790.	1.5	43
902	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. <i>Pharmacogenomics</i> , 2016, 17, 583-591.	0.6	9
903	Multifactorial Prevention of Cardiovascular Disease in Patients with Hypertension: the Cardiovascular Polypill. <i>Current Hypertension Reports</i> , 2016, 18, 40.	1.5	16
904	Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. , 2016, 164, 183-194.		20
905	Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 253, 88-93.	0.4	35

#	ARTICLE	IF	CITATIONS
906	Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 922-932.	5.5	26
907	Genipin crosslinked soy-whey based bioactive material for atorvastatin loaded nanoparticles: preparation, characterization and in vivo antihyperlipidemic study. <i>RSC Advances</i> , 2016, 6, 93275-93287.	1.7	16
909	Novel genipin crosslinked atorvastatin loaded sericin nanoparticles for their enhanced antihyperlipidemic activity. <i>Materials Science and Engineering C</i> , 2016, 69, 967-976.	3.8	52
910	Relationship between dyslipidemia and carotid plaques in a high-risk population in Shandong Province, China. <i>Brain and Behavior</i> , 2016, 6, e00473.	1.0	23
911	Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 252, 21-27.	0.4	27
912	Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia. <i>The Cochrane Library</i> , 2016, 2016, CD009462.	1.5	18
913	Statin use in patients with peripheral arterial disease. <i>Journal of Vascular Surgery</i> , 2016, 64, 1881-1888.	0.6	42
915	Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention. <i>Nutrition Research</i> , 2016, 36, 1162-1170.	1.3	40
916	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet</i> , 2016, 388, 2532-2561.	6.3	1,399
917	LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 323-336.	1.0	18
918	Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. <i>Atherosclerosis</i> , 2016, 251, 248-254.	0.4	61
919	A systematic review of interventions to improve adherence to statin medication: What do we know about what works?. <i>Preventive Medicine</i> , 2016, 90, 155-169.	1.6	31
920	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2016, 35, 537.	1.7	4
921	Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility. <i>Expert Review of Hematology</i> , 2016, 9, 1023-1030.	1.0	15
922	Use of statins and reduced risk of recurrence of VTE in an older population. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1220-1228.	1.8	18
923	Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. <i>BMJ</i> , 2016, 353, i3283.	3.0	167
924	Polypill. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 783-792.	0.6	4
925	Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study. <i>BMJ Open</i> , 2016, 6, e011734.	0.8	23

#	ARTICLE	IF	CITATIONS
926	AB0184â€¦Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 960.1-960.	0.5	0
927	A randomized clinical trial evaluating aÂproprietary mixture of <i>Lactobacillus plantarum</i> strains for lowering cholesterol1. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2016, 9, 125-135.	0.2	19
928	Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 161-169.	0.9	31
929	Community programmes for coronary heart disease in Spanish primary care. <i>International Journal of Health Planning and Management</i> , 2016, 31, 87-96.	0.7	0
930	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. <i>Journal of Translational Medicine</i> , 2016, 14, 83.	1.8	18
931	Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 241-253.	1.0	12
932	Statin use and risk of cataract: A nested case-control study within a healthcare database. <i>Atherosclerosis</i> , 2016, 251, 153-158.	0.4	20
933	Sick Populations and Sick Subpopulations. <i>Circulation</i> , 2016, 134, 472-485.	1.6	19
934	New perspectives on dairy and cardiovascular health. <i>Proceedings of the Nutrition Society</i> , 2016, 75, 247-258.	0.4	23
936	The NHS Health Checks programme: A better alternative. <i>Journal of Medical Screening</i> , 2016, 23, 57-58.	1.1	2
937	Head to head comparison of the propensity score and the high-dimensional propensity score matching methods. <i>BMC Medical Research Methodology</i> , 2016, 16, 22.	1.4	35
938	The OPTIMIZE trial: Rationale and design of a randomized controlled trial of motivational enhancement therapy to improve adherence to statin medication. <i>Contemporary Clinical Trials</i> , 2016, 49, 47-56.	0.8	2
939	Cholesterol trials and mortality. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 168-177.	1.1	17
940	Rosuvastatin Decreases Mean Platelet Volume in Patients With Diabetes Mellitus. <i>Angiology</i> , 2016, 67, 116-120.	0.8	21
941	Usefulness of the Polypill for the Prevention of Cardiovascular Disease and Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 14.	1.5	8
942	Particulate matter cytotoxicity in cultured SH-SY5Y cells is modulated by simvastatin: Toxicological assessment for oxidative damage. <i>NeuroToxicology</i> , 2016, 53, 108-114.	1.4	14
943	Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies. <i>Circulation</i> , 2016, 133, 256-264.	1.6	80
944	Dissolution enhancement of a model poorly water-soluble drug, atorvastatin, with ordered mesoporous silica: comparison of MSF with SBA-15 as drug carriers. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 171-181.	2.4	39

#	ARTICLE	IF	CITATIONS
945	Statins and risk of poststroke hemorrhagic complications. <i>Neurology</i> , 2016, 86, 1590-1596.	1.5	26
946	Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1289-1297.	0.8	13
947	Trans fat and cardiovascular disease mortality: Evidence from bans in restaurants in New York. <i>Journal of Health Economics</i> , 2016, 45, 176-196.	1.3	92
948	Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany. <i>Current Medical Research and Opinion</i> , 2016, 32, 417-426.	0.9	7
949	Association of Maternal Prepregnancy Dyslipidemia With Adult Offspring Dyslipidemia in Excess of Anthropometric, Lifestyle, and Genetic Factors in the Framingham Heart Study. <i>JAMA Cardiology</i> , 2016, 1, 26.	3.0	38
950	Grapefruit Juice and Statins. <i>American Journal of Medicine</i> , 2016, 129, 26-29.	0.6	57
951	Starting the polypill: the use of a single age cut-off in males and females. <i>Journal of Medical Screening</i> , 2017, 24, 50-53.	1.1	5
952	News from Tartary: an ethnopharmacological approach to drug and therapeutic discovery. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 33-37.	1.1	14
953	Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. <i>Journal of Medical Economics</i> , 2017, 20, 555-564.	1.0	49
954	Lipid and other management to improve arterial disease and survival in end stage renal disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 343-349.	0.9	3
955	Documento de consenso del uso cl�nico de la Polypill en la prevenci�n secundaria del riesgo cardiovascular. <i>Medicina Cl�nica</i> , 2017, 148, 139.e1-139.e15.	0.3	6
956	Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease. <i>Thrombosis Research</i> , 2017, 150, 90-95.	0.8	25
957	Functional foods and dietary supplements for the management of dyslipidaemia. <i>Nature Reviews Endocrinology</i> , 2017, 13, 278-288.	4.3	154
958	Association of the SPTLC3 rs364585 polymorphism and serum lipid profiles in two Chinese ethnic groups. <i>Lipids in Health and Disease</i> , 2017, 16, 1.	1.2	127
959	Evidence-based goals in LDL-C reduction. <i>Clinical Research in Cardiology</i> , 2017, 106, 237-248.	1.5	69
960	Inulin-type fructans have no significant beneficial effects on lipid or glucose metabolism. <i>European Journal of Clinical Nutrition</i> , 2017, 71, 677-677.	1.3	6
961	Lipid-lowering treatment modifications among patients with hyperlipidemia and a prior cardiovascular event: a US retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2017, 33, 869-876.	0.9	5
962	Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease. <i>Medicina Cl�nica (English Edition)</i> , 2017, 148, 139.e1-139.e15.	0.1	2

#	ARTICLE	IF	CITATIONS
963	When less is more – efficacy with less toxicity at the ED50. British Journal of Clinical Pharmacology, 2017, 83, 1365-1368.	1.1	32
964	Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis. Atherosclerosis, 2017, 261, 26-36.	0.4	37
965	PCSK9 as a therapeutic target for cardiovascular disease. Experimental and Therapeutic Medicine, 2017, 13, 810-814.	0.8	15
966	Time to improve statin prescription guidelines in low-risk patients?. European Journal of Preventive Cardiology, 2017, 24, 1064-1070.	0.8	8
967	Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants. Journal of Hypertension, 2017, 35, S33-S40.	0.3	5
968	The polypill in cardiovascular prevention. Journal of Hypertension, 2017, 35, 1546-1553.	0.3	48
969	Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. Journal of the Academy of Nutrition and Dietetics, 2017, 117, 251-264.	0.4	312
970	Increasing the Detection of Familial Hypercholesterolaemia Using General Practice Electronic Databases. Heart Lung and Circulation, 2017, 26, 450-454.	0.2	29
971	Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting. Stroke, 2017, 48, 1890-1894.	1.0	27
972	The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. European Heart Journal, 2017, 38, 2499-2507.	1.0	176
973	Lipid levels and risk of venous thrombosis: results from the MEGA-study. European Journal of Epidemiology, 2017, 32, 669-681.	2.5	35
974	High-Throughput Assay for Enantiomeric Excess Determination in 1,2- and 1,3-Diols and Direct Asymmetric Reaction Screening. Chemistry - A European Journal, 2017, 23, 10222-10229.	1.7	32
976	A Population-Based Analysis of Quality Indicators in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 727-733.	2.2	31
977	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 537-547.	1.7	18
978	A Healthy Balance of Plasma Cholesterol by a Novel Annurca Apple-Based Nutraceutical Formulation: Results of a Randomized Trial. Journal of Medicinal Food, 2017, 20, 288-300.	0.8	21
979	Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. European Journal of Preventive Cardiology, 2017, 24, 951-961.	0.8	23
980	Statin prescribing for people with severe mental illnesses: a staggered cohort study of “real-world” impacts. BMJ Open, 2017, 7, e013154.	0.8	12
981	Statins for primary prevention in people with a 10% 10-year cardiovascular risk: too much medicine too soon?. British Journal of General Practice, 2017, 67, 40-41.	0.7	5

#	ARTICLE	IF	CITATIONS
982	Statin potency and the risk of hospitalization for community-acquired pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1319-1327.	1.1	9
983	Investigating cholesterol metabolism and ageing using a systems biology approach. <i>Proceedings of the Nutrition Society</i> , 2017, 76, 378-391.	0.4	16
984	Maternal Undernutrition and Long-Term Effects on Hepatic Function. , 2017, , 107-120.		2
985	Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial) Tj ETQq1 1,0,784314 rgBT /Ove 1.6 495	1.6	495
986	ROCK as a therapeutic target for ischemic stroke. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1167-1177.	1.4	44
987	Cerivastatin for lowering lipids. <i>The Cochrane Library</i> , 0, , .	1.5	2
988	Association between plant-based diets and plasma lipids: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2017, 75, 683-698.	2.6	230
989	Reconstitutable spray dried ultra-fine dispersion as a robust platform for effective oral delivery of an antihyperlipidemic drug. <i>International Journal of Pharmaceutics</i> , 2017, 532, 478-490.	2.6	19
990	Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening. <i>BMJ Open</i> , 2017, 7, e015935.	0.8	17
992	Synthesis and characterization of hyaluronic acid coated manganese dioxide microparticles that act as ROS scavengers. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 159, 30-38.	2.5	23
993	The Effects of Vitamin D Supplementation on Glucose Metabolism and Lipid Profiles in Patients with Gestational Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Hormone and Metabolic Research</i> , 2017, 49, 647-653.	0.7	50
994	Uncoupling associations of risk alleles with endophenotypes and phenotypes: insights from the <i><i>ApoB</i></i> locus and heart-related traits. <i>Aging Cell</i> , 2017, 16, 61-72.	3.0	26
995	Prevalence of high-risk cardiovascular patients with therapy-resistant hypercholesterolemia. <i>Cardiovascular Endocrinology</i> , 2017, 6, 81-85.	0.8	6
998	Pitavastatin for lowering lipids. <i>The Cochrane Library</i> , 2017, , .	1.5	3
999	Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS II Study in Egypt. <i>Cardiology and Therapy</i> , 2017, 6, 105-120.	1.1	3
1000	Non-high-density lipoprotein cholesterol predicts nonfatal recurrent myocardial infarction in patients with ST segment elevation myocardial infarction. <i>Lipids in Health and Disease</i> , 2017, 16, 20.	1.2	24
1001	Genetic determinants of inherited susceptibility to hypercholesterolemia – a comprehensive literature review. <i>Lipids in Health and Disease</i> , 2017, 16, 103.	1.2	89
1003	Observational Prospective study to esTIMAtE the rates of outcomes in patients undergoing PCI with drug-eluting stent implantation who take statins –follow-up (OPTIMA II). <i>Current Medical Research and Opinion</i> , 2017, 33, 253-259.	0.9	0

#	ARTICLE	IF	CITATIONS
1004	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. <i>Clinical Research in Cardiology</i> , 2017, 106, 58-68.	1.5	23
1005	Diseaseâ€“Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2017, 56, 607-615.	1.6	62
1006	Anti-obesogenic and antidiabetic effects of plants and mushrooms. <i>Nature Reviews Endocrinology</i> , 2017, 13, 149-160.	4.3	213
1007	Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 76-83.	0.8	26
1008	The Need to Interpret the Results of a Clinical Trial in the Context of Other Evidence. <i>American Journal of Medicine</i> , 2017, 130, 251-252.	0.6	0
1009	Genetic polymorphisms as predictive markers for statin therapy: a route to improved cardiovascular patient outcomes?. <i>Bioscience Horizons</i> , 2017, 10, .	0.6	2
1010	Sicyos angulatus ameliorates atherosclerosis through downregulation of aortic inflammatory responses in apolipoprotein Eâ€“deficient mice. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 5863-5870.	0.8	5
1011	Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*. <i>Journal of Market Access & Health Policy</i> , 2017, 5, 1412753.	0.8	7
1012	The Adherence Rate Threshold is Drug Specific. <i>Drugs in R and D</i> , 2017, 17, 645-653.	1.1	18
1013	Population-Based Case-Control Study Assessing the Association between Statins Use and Pulmonary Tuberculosis in Taiwan. <i>Frontiers in Pharmacology</i> , 2017, 8, 597.	1.6	22
1014	Chitosan-based nanoparticulate systems for oral drug delivery. , 2017, , 607-638.		3
1015	Effects of Soluble Corn Fiber Alone or in Synbiotic Combination with <i>Lactobacillus rhamnosus</i> GG and the Pilus-Deficient Derivative GG-PB12 on Fecal Microbiota, Metabolism, and Markers of Immune Function: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Elderly (Saimes Study). <i>Frontiers in Immunology</i> , 2017, 8, 1443.	2.2	67
1016	Fatal Statin-Induced Rhabdomyolysis by Possible Interaction with Palbociclib. <i>Frontiers in Oncology</i> , 2017, 7, 150.	1.3	17
1017	Etiologic effects and optimal intakes of foods and nutrients for risk of cardiovascular diseases and diabetes: Systematic reviews and meta-analyses from the Nutrition and Chronic Diseases Expert Group (NutriCoDE). <i>PLoS ONE</i> , 2017, 12, e0175149.	1.1	287
1018	Cardiovascular Disease and Renal Transplantation. , 2017, , 543-554.		0
1019	Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-12.	1.0	9
1020	Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefitâ€“Based Lipid and Blood Pressure Treatment. <i>MDM Policy and Practice</i> , 2017, 2, 238146831772574.	0.5	3
1021	The Concept of the Polypill in the Prevention of Cardiovascular Disease. <i>Annals of Global Health</i> , 2018, 80, 24.	0.8	23

#	ARTICLE	IF	CITATIONS
1022	Fluvastatin for lowering lipids. The Cochrane Library, 2018, 2018, CD012282.	1.5	42
1023	Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: The Multi-Ethnic Study of Atherosclerosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 365-372.	0.9	7
1024	Involvement of IL-1 β and IL-6 in antiarrhythmic properties of atorvastatin in ouabain-induced arrhythmia in rats. <i>Immunopharmacology and Immunotoxicology</i> , 2018, 40, 256-261.	1.1	5
1025	Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TElmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study. <i>Clinical Therapeutics</i> , 2018, 40, 676-691.e1.	1.1	21
1026	Advances in Cardiovascular Care. <i>JACC Basic To Translational Science</i> , 2018, 3, 114-118.	1.9	0
1027	The pharmacodynamic and clinical trial evidence for statin dose. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1128-1135.	1.1	17
1028	Prognostic factors for resected non-small cell lung cancer in patients with type 2 diabetes mellitus. <i>Journal of Surgical Oncology</i> , 2018, 117, 985-993.	0.8	11
1029	Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. <i>Annals of Internal Medicine</i> , 2018, 168, 85.	2.0	60
1030	Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis. <i>CardioRenal Medicine</i> , 2018, 8, 105-112.	0.7	16
1031	Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. <i>European Heart Journal</i> , 2018, 39, 1740-1747.	1.0	51
1032	Statin related adverse effects and patient education: a study from resource limited settings. <i>Acta Cardiologica</i> , 2018, 73, 393-401.	0.3	9
1033	Analysis of <i>SLCO1B1</i> and <i>APOE</i> genetic polymorphisms in a large ethnic Hakka population in southern China. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, e22408.	0.9	10
1034	Advancement in nanotechnology-based approaches for the treatment and diagnosis of hypercholesterolemia. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 188-197.	1.9	6
1035	Statins: pros and cons. <i>Medicina Clínica</i> , 2018, 150, 398-402.	0.3	99
1036	A comparison of the effects of low- and high-dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: Results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 44-55.	0.6	15
1037	Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. <i>Drugs</i> , 2018, 78, 215-229.	4.9	33
1038	Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study. <i>Atherosclerosis</i> , 2018, 274, 54-60.	0.4	17
1039	Analytical Methods for the Determination of Rosuvastatin in Pharmaceutical Formulations and Biological Fluids: A Critical Review. <i>Critical Reviews in Analytical Chemistry</i> , 2018, 48, 317-329.	1.8	14

#	ARTICLE	IF	CITATIONS
1040	A consensus statement on lipid management after acute coronary syndrome. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 532-543.	0.4	27
1042	Research on the cause of death for severe stroke patients. <i>Journal of Clinical Nursing</i> , 2018, 27, 450-460.	1.4	18
1043	Familial hypercholesterolaemia in patients with ischaemic stroke or transient ischaemic attack. <i>European Journal of Neurology</i> , 2018, 25, 260-267.	1.7	11
1044	Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation. <i>European Journal of Internal Medicine</i> , 2018, 47, 25-31.	1.0	12
1045	Systemic mastocytosis associates with cardiovascular events despite lower plasma lipid levels. <i>Atherosclerosis</i> , 2018, 268, 152-156.	0.4	20
1046	Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 51-69.	0.7	8
1047	Statin Treatments And Dosages In Children With Familial Hypercholesterolemia: Meta-Analysis. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 810-821.	0.3	9
1048	Identification of 12 novel loci that confer susceptibility to early-onset dyslipidemia. <i>International Journal of Molecular Medicine</i> , 2018, 43, 57-82.	1.8	5
1049	Comparative analysis of the gut microbiota in distinct statin response patients in East China. <i>Journal of Microbiology</i> , 2018, 56, 886-892.	1.3	22
1050	The prediction of therapy-benefit for individual cardiovascular disease prevention. <i>Current Opinion in Lipidology</i> , 2018, 29, 436-444.	1.2	21
1051	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. <i>Atherosclerosis</i> , 2018, 277, 334-340.	0.4	33
1052	Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and KIF6 and HMG-CoA Genotypes in a Subset of the Brisighella Heart Study Population. <i>International Journal of Molecular Sciences</i> , 2018, 19, 49.	1.8	9
1053	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1857-1865.	0.9	16
1054	LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C. <i>Atherosclerosis</i> , 2018, 277, 327-333.	0.4	12
1055	Effect of Statins on Renal Function in Chronic Kidney Disease Patients. <i>Scientific Reports</i> , 2018, 8, 16276.	1.6	19
1056	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 846-984.	0.9	541
1057	Regenerative Medicine Therapies for Targeting Neuroinflammation After Stroke. <i>Frontiers in Neurology</i> , 2018, 9, 734.	1.1	52
1058	Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. <i>Atherosclerosis</i> , 2018, 278, 135-142.	0.4	20

#	ARTICLE	IF	CITATIONS
1059	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , 2018, 272, 20-25.	0.8	24
1060	A Score for Risk of Thrombolysis-Associated Hemorrhage Including Pretreatment with Statins. <i>Frontiers in Neurology</i> , 2018, 9, 74.	1.1	14
1061	Statins: pros and cons. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 398-402.	0.1	6
1062	Dietary Cholesterol, Serum Lipids, and Heart Disease: Are Eggs Working for or Against You?. <i>Nutrients</i> , 2018, 10, 426.	1.7	65
1063	A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations. <i>Scientia Pharmaceutica</i> , 2018, 86, 1.	0.7	22
1064	Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 269-281.	2.3	5
1065	The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. <i>Translational Neurodegeneration</i> , 2018, 7, 5.	3.6	147
1066	Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1Åyear: an open label, non-randomized, controlled study. <i>Cardiovascular Diabetology</i> , 2018, 17, 56.	2.7	135
1067	Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. <i>Journal of Clinical Epidemiology</i> , 2018, 104, 15-23.	2.4	4
1068	Antihyperlipidemic studies of newly synthesized phenolic derivatives: in silico and in vivo approaches. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2443-2453.	2.0	13
1069	Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 512-521.	0.8	11
1070	Effects of Statin Treatment on Outcomes after Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 118-125.	1.7	9
1071	Does the Benefit of Cholesterol-Lowering of a Given Magnitude Depend on the Drug Intervention Used?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005599.	0.9	1
1072	Size of carotid artery intraplaque hemorrhage and acute ischemic stroke: a cardiovascular magnetic resonance Chinese atherosclerosis risk evaluation study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2019, 21, 36.	1.6	31
1073	Dietary apple polyphenols supplementation enhances antioxidant capacity and improves lipid metabolism in weaned piglets. <i>Journal of Animal Physiology and Animal Nutrition</i> , 2019, 103, 1512-1520.	1.0	19
1074	LDL cholesterol response to statins and future risk of cardiovascular disease. <i>Heart</i> , 2019, 105, 1290.3-1291.	1.2	3
1075	Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome. <i>Reproductive Biology</i> , 2019, 19, 309-315.	0.9	21
1076	Association between variants of COQ2 and TNF-Î± genes and statin-induced toxicities in Bangladeshi hyperlipidemic patients. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 621-626.	0.3	1

#	ARTICLE	IF	CITATIONS
1077	The effect of HMG-CoA reductase inhibitors on thrombolysis-induced haemorrhagic transformation. <i>Journal of Clinical Neuroscience</i> , 2019, 69, 1-6.	0.8	6
1078	Association of Specialist Physician Payment Model With Visit Frequency, Quality, and Costs of Care for People With Chronic Disease. <i>JAMA Network Open</i> , 2019, 2, e1914861.	2.8	9
1079	Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1583-1590.	0.9	7
1080	Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysis. <i>Medical Journal of Australia</i> , 2019, 211, 284.	0.8	2
1081	Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q ₁₀ . <i>Circulation</i> , 2019, 23, .		10
1082	12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia—Data From a Real-World Observational Study of Evolocumab in Japan. <i>Circulation Reports</i> , 2019, 1, 219-227.	0.4	4
1083	Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat. <i>JAMA Cardiology</i> , 2019, 4, 1131.	3.0	47
1084	Worldwide Dyslipidemia Guidelines. <i>Current Cardiovascular Risk Reports</i> , 2019, 13, 1.	0.8	17
1086	<p>High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease</p>. <i>The Application of Clinical Genetics</i> , 2019, Volume 12, 71-78.	1.4	15
1087	Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study. <i>Atherosclerosis</i> , 2019, 287, 8-15.	0.4	24
1088	A revised systematic review and meta-analysis on the effect of statins on D-dimer levels. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13130.	1.7	14
1089	Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease. <i>Atherosclerosis: X</i> , 2019, 39, 100002.	0.0	9
1090	Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 825-833.	1.5	13
1091	Urban-rural differences in the association between blood lipids and characteristics of the built environment: a systematic review and meta-analysis. <i>BMJ Global Health</i> , 2019, 4, e001017.	2.0	27
1092	Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. <i>Heart</i> , 2019, 105, 975-981.	1.2	86
1093	Effects of Preoperative Statin on Acute Kidney Injury After Off-pump Coronary Artery Bypass Grafting. <i>Journal of the American Heart Association</i> , 2019, 8, e010892.	1.6	13
1094	Serum Level of Total Lipids and Telomere Length in the Male Population: A Cross-Sectional Study. <i>American Journal of Men's Health</i> , 2019, 13, 155798831984297.	0.7	13
1095	Review: In dyslipidemia or atherosclerotic CVD, alirocumab and evolocumab vs control each reduce MI and stroke. <i>Annals of Internal Medicine</i> , 2019, 171, JC56.	2.0	5

#	ARTICLE	IF	CITATIONS
1096	Perinatal Malnutrition and Epigenetic Regulation of Long-Term Metabolism. , 2019, , 439-455.		0
1097	Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American Heart Journal, 2019, 210, 18-28.	1.2	102
1098	High concentrations of atorvastatin reduce <i>in-vitro</i> function of conventional T and regulatory T cells. Clinical and Experimental Immunology, 2019, 196, 237-248.	1.1	12
1099	PGC-1 β modulates statin-associated myotoxicity in mice. Archives of Toxicology, 2019, 93, 487-504.	1.9	17
1100	Evaluating statin effect on LDL-cholesterol: when predicted is not measured. European Journal of Preventive Cardiology, 2020, 27, 1627-1629.	0.8	0
1101	Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. European Journal of Preventive Cardiology, 2020, 27, 1630-1636.	0.8	23
1102	Prescription switching: Rationales and risks. International Journal of Clinical Practice, 2020, 74, e13429.	0.8	4
1103	A Structural Model of Correlated Learning and Late-Mover Advantages: The Case of Statins. Management Science, 2020, 66, 1095-1123.	2.4	15
1104	Small Dense Low-Density Lipoprotein Cholesterol and the Risk of Coronary Heart Disease in a Japanese Community. Journal of Atherosclerosis and Thrombosis, 2020, 27, 669-682.	0.9	52
1105	Effect of the herbal medicines in obesity and metabolic syndrome: A systematic review and meta-analysis of clinical trials. Phytotherapy Research, 2020, 34, 526-545.	2.8	86
1106	Risk Factors for Cholecystectomy After Laparoscopic Roux-En-Y Gastric Bypass. Obesity Surgery, 2020, 30, 507-514.	1.1	15
1107	Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study. BMJ Open, 2020, 10, e036920.	0.8	3
1108	Predicting Lipid-Lowering Medication Persistence after the First Cardiovascular Disease Hospitalization. Methods of Information in Medicine, 2020, 59, 061-074.	0.7	2
1109	Metabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in non-small cell lung cancer. Molecular Oncology, 2020, 14, 3135-3152.	2.1	30
1110	Effect of Lactobacillus plantarum HT121 on serum lipid profile, gut microbiota, and liver transcriptome and metabolomics in a high-cholesterol diet-induced hypercholesterolemia rat model. Nutrition, 2020, 79-80, 110966.	1.1	18
1111	SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. Atherosclerosis, 2020, 306, 41-49.	0.4	30
1112	Effects of α -linolenic acid intake on blood lipid profiles: a systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Food Science and Nutrition, 2021, 61, 2894-2910.	5.4	48
1113	The application and value of continuous nursing in patients after coronary artery bypass grafting. Journal of Cardiothoracic Surgery, 2020, 15, 168.	0.4	4

#	ARTICLE	IF	CITATIONS
1114	Pravastatin for lowering lipids. The Cochrane Library, 2020, , .	1.5	1
1115	Statin use in patients with <scp>nonâ€œHMGCR</scp> idiopathic inflammatory myopathies: A retrospective study. Clinical Cardiology, 2020, 43, 732-742.	0.7	12
1116	The Impact of Information Technology on the Diffusion of New Pharmaceuticals. American Economic Journal: Applied Economics, 2020, 12, 1-39.	1.5	5
1117	Factors Associated with the Prescribing of High-Intensity Statins. Journal of Clinical Medicine, 2020, 9, 3850.	1.0	2
1118	Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. Journal of Cardiovascular Pharmacology, 2020, 76, 658-670.	0.8	9
1119	Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia. Clinical Genetics, 2020, 98, 457-467.	1.0	13
1120	The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. Circulation, 2020, 142, 827-837.	1.6	44
1121	Statin use and safety concerns: an overview of the past, present, and the future. Expert Opinion on Drug Safety, 2020, 19, 1011-1024.	1.0	15
1122	Prevention of Stroke by Lowering Blood Cholesterol Concentrations. , 2020, , 297-307.		0
1123	Performance and clinical utility of supervised machine-learning approaches in detecting familial hypercholesterolaemia in primary care. Npj Digital Medicine, 2020, 3, 142.	5.7	21
1124	Autocrine effects of PCSK9 on cardiomyocytes. Basic Research in Cardiology, 2020, 115, 65.	2.5	16
1125	Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70â€œ100 years: a contemporary primary prevention cohort. Lancet, The, 2020, 396, 1644-1652.	6.3	143
1126	Cholesterol Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol Level. Cell Host and Microbe, 2020, 28, 245-257.e6.	5.1	151
1127	Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults. Journal of the American College of Cardiology, 2020, 76, 17-27.	1.2	27
1128	Pitavastatin for lowering lipids. The Cochrane Library, 2020, 2020, CD012735.	1.5	19
1129	Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options. Drugs and Aging, 2020, 37, 567-584.	1.3	9
1130	Measuring LDL-cholesterol: what is the best way to do it?. Current Opinion in Cardiology, 2020, 35, 405-411.	0.8	36
1131	Eligibility for PCSK-9 inhibitors treatment in acute coronary syndrome, chronic coronary artery disease and outpatient dyslipidemic patients. Atherosclerosis, 2020, 303, 29-35.	0.4	5

#	ARTICLE	IF	CITATIONS
1132	Statin prescription among patients with type 2 diabetes in Botswana: findings and implications. <i>BMC Endocrine Disorders</i> , 2020, 20, 36.	0.9	15
1133	Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. <i>Advances in Therapy</i> , 2020, 37, 1724-1736.	1.3	32
1134	Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia. <i>Journal of Lipid and Atherosclerosis</i> , 2020, 9, 162.	1.1	6
1135	The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations. <i>European Journal of Applied Physiology</i> , 2020, 120, 1205-1225.	1.2	8
1136	Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance. <i>Atherosclerosis</i> , 2020, 306, 33-40.	0.4	14
1137	Turning genome-wide association study findings into opportunities for drug repositioning. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 1639-1650.	1.9	21
1138	Statin use and risk of joint replacement due to osteoarthritis and rheumatoid arthritis: a propensity-score matched longitudinal cohort study. <i>Rheumatology</i> , 2020, 59, 2898-2907.	0.9	11
1139	Your results may vary: the imprecision of medical measurements. <i>BMJ</i> , The, 2020, 368, m149.	3.0	34
1140	The case for statin use to reduce perioperative adverse cardiovascular and cerebrovascular events. <i>British Journal of Anaesthesia</i> , 2020, 124, 525-534.	1.5	1
1141	Influence of Statins on Circulating Inflammatory Cytokines in Patients With Abnormal Glucose Homeostasis: A Meta-analysis of Data From Randomized Controlled Trials. <i>Clinical Therapeutics</i> , 2020, 42, e13-e31.	1.1	5
1142	Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-8.	1.1	7
1143	Community intervention for cardiovascular disease risk factors in Kalutara, Sri Lanka. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 203.	0.7	1
1144	Incorporation of genetic testing significantly increases the number of individuals diagnosed with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2020, 14, 331-338.	0.6	4
1145	2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 3005-3015.	1.0	33
1146	Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 634-646.	1.8	26
1147	Statin Lipophilicity and the Risk of Incident Heart Failure. <i>Cardiology</i> , 2020, 145, 375-383.	0.6	1
1148	Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 479-489.	1.3	11
1149	Enhancing feedback on performance measures: the difference in outlier detection using a binary versus continuous outcome funnel plot and implications for quality improvement. <i>BMJ Quality and Safety</i> , 2021, 30, 38-45.	1.8	6

#	ARTICLE	IF	CITATIONS
1150	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 59-65.	0.8	30
1151	Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 153-166.	1.3	15
1152	Association between healthcare practitioners' beliefs about statins and patients' beliefs and adherence. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1082-1088.	1.1	5
1153	The Ecology of Antihypertensives in the United States, 1997â€“2017. <i>Journal of General Internal Medicine</i> , 2021, 36, 699-704.	1.3	4
1154	Dietary dihydromyricetin supplementation enhances antioxidant capacity and improves lipid metabolism in finishing pigs. <i>Food and Function</i> , 2021, 12, 6925-6935.	2.1	20
1155	Genetic Association Studies of Age-Related Traits: New Perspectives. <i>Advances in Geriatric Medicine and Research</i> , 2021, 3, .	0.6	0
1156	Bempedoic acid: Review of a novel therapy in lipid management. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 95-104.	0.5	5
1157	Impact of statin pretreatment on the complications of carotid stenting in asymptomatic patients: observational study. <i>BMC Neurology</i> , 2021, 21, 75.	0.8	1
1158	Development and Validation of a Predictive Model for Coronary Artery Disease Using Machine Learning. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 614204.	1.1	9
1159	Patients With <i>LDLR</i> and <i>PCSK9</i> Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia. <i>Journal of the American Heart Association</i> , 2021, 10, e018263.	1.6	15
1160	Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack. <i>BMC Medicine</i> , 2021, 19, 24.	2.3	3
1161	Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment. <i>American Journal of Epidemiology</i> , 2021, 190, 2000-2014.	1.6	16
1162	The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 958-965.	1.0	7
1163	Assessment of exopolysaccharides, bacteriocins and in vitro and in vivo hypocholesterolemic potential of some Egyptian <i>Lactobacillus</i> spp.. <i>International Journal of Biological Macromolecules</i> , 2021, 173, 66-78.	3.6	15
1164	Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2021, 165, 105413.	3.1	10
1165	Identification of Statinâ€™s Action in a Small Cohort of Patients with Major Depression. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 2827.	1.3	0
1166	Polypill in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1673-1677.	13.9	1
1167	TRS2P and LDL-C alone or in combination for predicting absolute benefits from additional LDL-C lowering: Analysis from the TNT trial. <i>Atherosclerosis</i> , 2021, 322, 8-14.	0.4	2

#	ARTICLE	IF	CITATIONS
1168	Cholesterol lowering in secondary prevention: Could do better. <i>Atherosclerosis</i> , 2021, 324, 112-114.	0.4	2
1169	Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	3
1170	General Perspectives for the Treatment of Atherosclerosis. <i>Letters in Drug Design and Discovery</i> , 2021, 18, 314-324.	0.4	0
1171	Potential impact of gradual reduction of fat content in manufactured and out-of-home food on obesity in the United Kingdom: a modeling study. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1312-1321.	2.2	4
1172	Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users. <i>Health Technology Assessment</i> , 2021, 25, 1-234.	1.3	6
1173	Cardiovascular disease and meaning in life: A systematic literature review and conceptual model. <i>Palliative and Supportive Care</i> , 2021, 19, 367-376.	0.6	9
1174	Assessing the effects of inulin-type fructan intake on body weight, blood glucose, and lipid profile: A systematic review and meta-analysis of randomized controlled trials. <i>Food Science and Nutrition</i> , 2021, 9, 4598-4616.	1.5	21
1176	Chaotropic salts impact in HPLC approaches for simultaneous analysis of hydrophilic and lipophilic drugs. <i>Journal of Separation Science</i> , 2021, 44, 2908-2916.	1.3	11
1177	Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study. <i>Thrombosis Journal</i> , 2021, 19, 45.	0.9	8
1178	Plausible Positive Effects of Statins in COVID-19 Patient. <i>Cardiovascular Toxicology</i> , 2021, 21, 781-789.	1.1	6
1179	Grado de control lipídico de un Área de Gestión Sanitaria en pacientes de muy alto riesgo cardiovascular. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 198-202.	0.4	1
1180	Degree of lipid control in a Healthcare Management Area in patients at very high cardiovascular risk. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2021, 33, 198-202.	0.1	0
1181	Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e041673.	0.8	6
1182	Can Clinicians Start Prescribing Inclisiran for Hypercholesterolemia Today? A Review of Clinical Studies for Internal Medicine Physicians and Endocrinologists. <i>Cureus</i> , 2021, 13, e16664.	0.2	3
1183	Inclusion of <i>Citrullus colocynthis</i> Seed Extract into Diets Induced a Hypolipidemic Effect and Improved Layer Performance. <i>Agriculture (Switzerland)</i> , 2021, 11, 808.	1.4	8
1184	Statins and neuroprotective effects. <i>Praktik Lärjournal</i> , 2021, 17, e19-e27.	0.0	0
1185	Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis. <i>American Journal of Cardiology</i> , 2021, 154, 22-28.	0.7	4
1187	Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial. <i>Atherosclerosis</i> , 2021, 334, 57-65.	0.4	7

#	ARTICLE	IF	CITATIONS
1188	Cerivastatin for lowering lipids. The Cochrane Library, 2020, 1, CD012501.	1.5	12
1189	The Drivers of Health Trends: A Decomposition of Projected Health for Local Areas in England. Applied Demography Series, 2017, , 21-40.	0.1	3
1190	Agent Based Modeling of Atherosclerosis: A Concrete Help in Personalized Treatments. Lecture Notes in Computer Science, 2009, , 386-396.	1.0	7
1191	Translation from the Quantified Implicit Process Flow Abstraction in SBGN-PD Diagrams to Bio-PEPA Illustrated on the Cholesterol Pathway. Lecture Notes in Computer Science, 2011, , 13-38.	1.0	4
1192	Colesterol LDL, cuanto más bajo mejor. Clínica E Investigación En Arteriosclerosis, 2019, 31, 16-27.	0.4	16
1193	Balancing cardiovascular benefit and diabetogenic harm of therapy with statins: Real-world evidence from Italy. Diabetes Research and Clinical Practice, 2020, 164, 108197.	1.1	3
1194	Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet, The, 2005, 365, 434-41.	6.3	283
1195	The Tyranny of Public Health Campaigns. PsycCritiques, 2008, 53, .	0.0	1
1196	Aspirin for primary prevention: yes or no?. Journal of Primary Health Care, 2010, 2, 92.	0.2	6
1197	Prevention and Control of Chronic Diseases. , 2007, , 402-426.		10
1198	Family-based studies applied to the influence of early life factors on cardiovascular disease. , 2009, , 263-278.		1
1199	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic“therapeutic pathway in Italy. European Heart Journal Supplements, 2017, 19, D3-D54.	0.0	19
1200	Statin Therapy within the Perioperative Period. Anesthesiology, 2008, 108, 1141-1146.	1.3	70
1202	Lipid-modifying therapy. , 2007, , 258-291.		1
1203	Screening for Future Cardiovascular Disease Using Age Alone Compared with Multiple Risk Factors and Age. PLoS ONE, 2011, 6, e18742.	1.1	95
1204	An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (â€œPolypillâ€œ) in People with Raised Cardiovascular Risk. PLoS ONE, 2011, 6, e19857.	1.1	114
1205	Association of Primary Care Characteristics with Variations in Mortality Rates in England: An Observational Study. PLoS ONE, 2012, 7, e47800.	1.1	24
1206	The Efficacy and Tolerability of â€œPolypillsâ€œ™: Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 2012, 7, e52145.	1.1	74

#	ARTICLE	IF	CITATIONS
1207	Characteristics of High Risk People with Cardiovascular Disease in Chinese Rural Areas: Clinical Indicators, Disease Patterns and Drug Treatment. PLoS ONE, 2013, 8, e54169.	1.1	15
1208	Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events. PLoS ONE, 2014, 9, e90325.	1.1	6
1209	A Cluster Randomised Controlled Trial of a Pharmacist-Led Collaborative Intervention to Improve Statin Prescribing and Attainment of Cholesterol Targets in Primary Care. PLoS ONE, 2014, 9, e113370.	1.1	35
1210	Quantifying the Contribution of Statins to the Decline in Population Mean Cholesterol by Socioeconomic Group in England 1991 - 2012: A Modelling Study. PLoS ONE, 2015, 10, e0123112.	1.1	10
1211	Use of Medications and Lifestyles of Hypertensive Patients with High Risk of Cardiovascular Disease in Rural China. PLoS ONE, 2015, 10, e0124484.	1.1	14
1212	Pharmacodynamic Impact of Carboxylesterase 1 Gene Variants in Patients with Congestive Heart Failure Treated with Angiotensin-Converting Enzyme Inhibitors. PLoS ONE, 2016, 11, e0163341.	1.1	6
1213	Allostatic load as a predictor of all-cause and cause-specific mortality in the general population: Evidence from the Scottish Health Survey. PLoS ONE, 2017, 12, e0183297.	1.1	79
1214	Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England. PLoS ONE, 2018, 13, e0190688.	1.1	15
1215	Management of lipids in adults with diabetes mellitus and nephropathy and/or chronic kidney disease: summary of joint guidance from the Association of British Clinical Diabetologists (ABCD) and the Renal Association (RA). British Journal of Diabetes, 2017, 17, 64.	0.1	17
1216	Renoprotective efficacy of different doses of statins in experimental acute renal failure. Fiziolohichniy Zhurnal (Kiev, Ukraine: 1994), 2014, 60, 75-81.	0.1	3
1218	CENTRALISED SURVEY ON THE UNDERTREATMENT OF THE HYPERCHOLESTEROLEMIA IN RUSSIA (CEPHEUS). Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 67-74.	0.4	4
1219	The Statins in Prevention of Coronary Heart Diseases in Type 2 Diabetics. Bosnian Journal of Basic Medical Sciences, 2009, 9, 71-76.	0.6	15
1220	Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death. Oncotarget, 0, 7, 42208-42215.	0.8	29
1221	Statins in older adults. Australian Prescriber, 2013, 36, 79-82.	0.5	30
1223	A Structural Analysis of Detailing, Publicity and Correlated Learning: The Case of Statins. SSRN Electronic Journal, 0, , .	0.4	1
1224	Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors. Current Medicinal Chemistry, 2020, 27, 4494-4521.	1.2	1
1225	Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. Current Pharmaceutical Design, 2019, 25, 85-95.	0.9	11
1226	Web-Based Interventions Targeting Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2016, 18, e55.	2.1	116

#	ARTICLE	IF	CITATIONS
1227	Use of Statins in an Australian Elderly Population. International Journal of Clinical Cardiology, 2014, 1, .	0.1	4
1228	Effect of Six Months of Aerobic Exercise on Lipid Profile, Inflammatory Markers and Risk Factors of Cardiovascular Disease in Obese Women. Medical Laboratory Journal, 2018, 12, 32-37.	0.1	2
1229	Acute and Subacute Toxicological Study of the Aqueous Extract of the Stem Bark of Khaya Grandifoliola (Meliaceae) in Wistar Rats. Journal of Pharmaceutical and Medicinal Research, 2020, 5, 106-111.	0.1	2
1230	Measurement of baseline total cholesterol: new data from The Health Improvement Network (THIN) database. Primary Care Cardiovascular Journal, 2008, 1, 107.	0.1	7
1231	Trends in Cardiovascular Risk Factors Among Patients With Coronary Heart Disease. Deutsches Ärztblatt International, 2012, 109, 303-10.	0.6	20
1232	Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technology Assessment, 2009, 13, 1-74, 75-118.	1.3	30
1233	Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation.. Health Technology Assessment, 2012, 16, 1-236, iii-iv.	1.3	98
1234	Outcomes of a multidisciplinary approach to the management of the metabolic syndrome. Canadian Pharmacists Journal, 2008, 141, 42-47.	0.4	3
1235	Change in Framingham Risk Score in Patients With Schizophrenia. Primary Care Companion To the Journal of Clinical Psychiatry, 2006, 8, 329-33.	0.6	9
1236	Statin intolerance. Journal of Postgraduate Medicine, 2011, 57, 321-328.	0.2	25
1237	Statins and its hepatic effects: Newer data, implications, and changing recommendations. Journal of Pharmacy and Bioallied Sciences, 2016, 8, 23.	0.2	64
1238	Statin Hepatotoxicity: Is it a Real Concern?. Heart Views, 2011, 12, 104.	0.1	7
1239	Brand versus Generic Rosuvastatin in Egyptian Patients with Hyperlipidemia; Cost-Minimization Analysis. International Journal of Clinical Medicine, 2019, 10, 631-638.	0.1	2
1240	The Application of the LDL Principle. World Journal of Cardiovascular Diseases, 2016, 06, 109-125.	0.0	12
1241	Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk Outcome. Oman Medical Journal, 2015, 30, 403-405.	0.3	1
1242	Treatment - Drug Therapy. Journal of Atherosclerosis and Thrombosis, 2008, 15, 167-178.	0.9	4
1243	CEPHEUS SA : a South African survey on the undertreatment of hypercholesterolaemia : cardiovascular topics. Cardiovascular Journal of Africa, 2011, 22, 234-240.	0.2	16
1244	Guideline For Stable Coronary Artery Disease. Arquivos Brasileiros De Cardiologia, 2014, 103, 1-56.	0.3	38

#	ARTICLE	IF	CITATIONS
1246	Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care. <i>Open Heart</i> , 2021, 8, e001817.	0.9	10
1247	A healthy heart in a single pill. <i>Nature</i> , 0, , .	13.7	0
1248	Verordnungsprofil der Internisten. , 2004, , 1013-1041.		0
1249	Lipidsenkende Mittel. , 2004, , 641-658.		0
1250	The effectiveness and safety of Tulip in patients with hyperlipidemia. <i>Arterial Hypertension (Russian)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.1	0
1251	Statins: the case for higher, individualized starting doses.. <i>Cleveland Clinic Journal of Medicine</i> , 2005, 72, 811-816.	0.6	5
1252	Diabetes, Obesity, and Metabolic Syndrome. <i>Nutrition and Disease Prevention</i> , 2006, , 1-30.	0.1	2
1253	Triglycerides and Risk for Atherosclerotic Disease. <i>Fundamental and Clinical Cardiology</i> , 2006, , 341-388.	0.0	0
1254	Management of Elevated Low-Density Lipoprotein Cholesterol. <i>Fundamental and Clinical Cardiology</i> , 2006, , 255-294.	0.0	0
1255	Cerebrovascular Disease in Hypertension. , 2007, , 392-405.		0
1256	Biology and imaging of vascular inflammation and atherosclerosis.. <i>Juntendoì,, Igaku</i> , 2007, 53, 20-30.	0.1	0
1257	Carotid Artery Intervention. , 2007, , 1741-1753.		0
1258	Laboratory medicine in primary care Lipid management. <i>BMJ, The</i> , 2007, 334, 070259.	3.0	0
1259	Optimising use of statins in clinical practice: how to achieve the best clinical outcomes for every patient. <i>Primary Care Cardiovascular Journal</i> , 2008, 1, .	0.1	0
1260	NHG-Standpunt Diagnostiek en behandeling van familiale hypercholesterolemie. , 2009, , 153-159.		0
1261	Statins and familial hypercholesterolaemia. <i>BMJ: British Medical Journal</i> , 2009, 338, a3041-a3041.	2.4	1
1262	Clinical Pharmacology of Cardiovascular Drugs. , 2009, , 367-402.		0
1263	Zijn cholesterolverlagende margarines werkzaam en is er een interactie met statines?. , 2010, , 11-19.		0

#	ARTICLE	IF	CITATIONS
1264	Biomarkers. , 2010, , 225-239.		0
1267	Gender Differences in Stroke. , 2010, , 129-135.		2
1268	Strategies for Treating Abnormal Lipid Profiles with Drugs. , 2011, , 163-193.		1
1269	Drug Therapy and Follow-Up. , 2011, , 563-631.		0
1270	Kardiovaskuläre Risikofaktoren und deren therapeutische Beeinflussung. , 2011, , 1-12.		1
1271	Population Genomics of Heart Diseases and Risk Factors: Going Wider and Deeper. North American Journal of Medicine & Science, 2011, 4, 249.	3.8	0
1272	High Degree of Adherence to Statin Therapy Among the Elderly Despite High Frequency of Side Effects. Healthy Aging & Clinical Care in the Elderly, 0, 3, 1-7.	0.7	0
1273	Statins: Side effects and drug interactions. Scripta Medica, 2011, 42, 84-91.	0.0	0
1276	Application of secondary prevention measures in patients with coronary artery disease - Republic Serbia. Srce I Krvni Sudovi, 2011, 30, 234-240.	0.1	2
1277	CPAP therapy: Results of randomized controlled trials in obstructive sleep apnea. , 2011, , 475-500.		0
1278	calculated-10-years-risk-of-chd-primary-preventive-measures-in-medical-ward-ppukm-university-kebangsaan-malaysia-medical-centre. Malaysian Journal of Pharmacy, 2011, 1, 336-344.	0.2	0
1279	Mitochondrial Proteomics: From Structure to Function. , 0, , .		0
1280	Differential Effect of Everolimus on Progression of Early and Late Cardiac Allograft Vasculopathy in Current Clinical Practice. American Journal of Transplantation, 2013, , n/a-n/a.	2.6	2
1281	Biomarkers and Endpoints in Rare Diseases. , 0, , 557-561.		0
1284	Prevention of Cardiovascular Disease: The Polypill Concept. , 2015, , 613-632.		0
1285	An Overview of Treatment and Guidelines: ESC/ACC-AHA/NICE. , 2015, , 33-56.		0
1286	The Effect of Generic Entry on the Demand for Pharmaceutical Products. The Journal of Eurasian Studies, 2015, 12, 235-244.	0.1	0
1287	Statin Myopathy. , 2016, , 113-122.		0

#	ARTICLE	IF	CITATIONS
1288	14.ÂDyslipidemia. , 2016, , .		0
1290	COMPLICATIONS OF STATIN THERAPY AND THEIR MANAGEMENT. Journal of Evolution of Medical and Dental Sciences, 2016, 5, 4745-4750.	0.1	0
1291	Glycemic Index and Cardiovascular Disease Risk Prevention and Management. , 2016, , 79-105.		0
1292	En veltrent kvinne i 30-Ã¥rene med anstrengelsesdyspnÃ©. Tidsskrift for Den Norske Laegeforening, 2017, 137, 456-458.	0.2	1
1293	Perinatal Malnutrition and Epigenetic Regulation of Long-Term Metabolism. , 2017, , 1-17.		0
1294	Effect of Genetic Polymorphisms in Detoxification Proteins on Treatment Outcome of Atorvastatin. International Journal of Pharmacology, 2017, 13, 198-204.	0.1	0
1295	Comparative Analysis of Alternate Day and Daily Regimen of Atorvastatin in Dyslipidaemic South Indian Patients. International Journal of Pharmacology and Clinical Sciences, 2017, 5, 97-102.	0.1	0
1296	Effect of Stem Cells versus Statins on the Mucous Membrane and Salivary Glands of the Tongue of Induced- Diabetic Rats. Suez Canal University Medical Journal, 2017, 20, 190-200.	0.0	0
1298	Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabÃ©tique. , 2019, , 377-390.		0
1300	Investigating the effect of atorvastatin drug on HbA1c in patients with myocardial infarction hospitalized in Farshchian Hospital, Hamadan province, Iran, in 2014-2015 (a before-after study). Electronic Journal of General Medicine, 2019, 16, em111.	0.3	0
1302	Bitkisel Sterollerin/Stanollerin Aterosklerotik SÃ¼reÃ§ ve KardiyovaskÃ¼ler HastalÄ±klar Ãœzerine Etkisi. Sakarya Medical Journal, 0, , .	0.1	0
1306	Lipidsenkende Mittel. , 0, , 698-715.		0
1309	POLYPILL ADMINISTRATION IS IT MANDATORY FOR CARDIOVASCULAR DISEASE PREVENTION?. , 2020, , 1-3.		0
1310	Lipid-lowering therapy in patients with coronary artery disease in primary care practices: what has changed over 7 years?. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2609.	0.4	2
1311	Influence of statinâ€¢potency on the risk of kidney disease â€¢ A nationwide cohort study using laboratory data. Pharmacoepidemiology and Drug Safety, 2021, 30, 210-219.	0.9	1
1312	The New Target of Vulnerable Plaque. International Heart Journal, 2020, 61, 1091-1093.	0.5	1
1313	Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study. BJGP Open, 2020, 4, bjgpopen20X101114.	0.9	8
1314	Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol. BJGP Open, 2021, 5, bjgpopen20X101127.	0.9	3

#	ARTICLE	IF	CITATIONS
1315	Rosuvastatin: an independent analysis of risks and benefits. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 73.	0.2	9
1316	The use of cardiovascular risk factor information in practice databases: making the best of patient data. <i>British Journal of General Practice</i> , 2006, 56, 600-5.	0.7	7
1318	Cholesterol lowering for secondary prevention: what statin dose should we use?. <i>Vascular Health and Risk Management</i> , 2007, 3, 615-27.	1.0	8
1319	Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. <i>Vascular Health and Risk Management</i> , 2007, 3, 711-9.	1.0	3
1321	The independent relationship between triglycerides and coronary heart disease. <i>Vascular Health and Risk Management</i> , 2009, 5, 89-95.	1.0	54
1322	Practical use of the Framingham risk score in primary prevention: Canadian perspective. <i>Canadian Family Physician</i> , 2011, 57, 417-23.	0.1	38
1323	Variation in prescription use and spending for lipid-lowering and diabetes medications in the Veterans Affairs Healthcare System. <i>American Journal of Managed Care</i> , 2010, 16, 741-50.	0.8	17
1324	Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. <i>AMIA ... Annual Symposium proceedings</i> , 2011, 2011, 1270-9.	0.2	23
1325	Aberrant promoter methylation profile of Niemann-pick type C1 gene in cardiovascular disease. <i>Iranian Biomedical Journal</i> , 2013, 17, 77-83.	0.4	7
1326	Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 5978-88.	1.3	9
1327	Anticoagulants and Statins As Pharmacological Agents in Free Flap Surgery: Current Rationale. <i>Eplasty</i> , 2015, 15, e51.	0.4	7
1328	LDL Cholesterol Goal Attainment in Hypercholesterolemia: CEPHEUS Indonesian Survey. <i>Acta Cardiologica Sinica</i> , 2013, 29, 71-81.	0.1	6
1329	Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 497-504.	0.8	15
1330	Price versus clinical guidelines in primary care statin prescribing: a retrospective cohort study and cost simulation model. <i>Journal of the Royal Society of Medicine</i> , 2022, 115, 100-111.	1.1	2
1331	Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003853.	3.9	22
1332	Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. <i>PLoS ONE</i> , 2021, 16, e0260839.	1.1	4
1333	Prevention of atherosclerosis from childhood. <i>Nature Reviews Cardiology</i> , 2022, 19, 543-554.	6.1	50
1334	Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. <i>Atherosclerosis</i> , 2022, 341, 20-26.	0.4	3

#	ARTICLE	IF	CITATIONS
1335	Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF- α expressions affecting oxidative/nitrosative stress and inflammation. <i>Human and Experimental Toxicology</i> , 2022, 41, 096032712110660.	1.1	5
1336	An effector index to predict target genes at GWAS loci. <i>Human Genetics</i> , 2022, 141, 1431-1447.	1.8	28
1337	Risk Factors for Symptomatic Gallstone Disease and Gallstone Formation After Bariatric Surgery. <i>Obesity Surgery</i> , 2022, 32, 1270-1278.	1.1	16
1338	High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. <i>Current Atherosclerosis Reports</i> , 2007, 9, 5-6.	2.0	1
1339	Effects of lipoproteins on yolk microstructure in duck, quail, goose, pigeon, and chicken eggs. <i>Food Science and Technology</i> , 0, 42, .	0.8	1
1340	Impact of physicianâ€™ and pharmacy staff supporting activities in usual care on patientsâ€™ statin adherence. <i>PLoS ONE</i> , 2022, 17, e0264555.	1.1	0
1342	The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial. <i>Frontiers in Pharmacology</i> , 2022, 13, 755469.	1.6	5
1343	Could Phosphate Provide a Second Chance for Statin Therapy in Kidney Failure?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 478-480.	2.2	0
1345	Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach. <i>Pharmacogenomics Journal</i> , 2022, , .	0.9	0
1346	Blood pressure meta-analysis highlights an implementation gap. <i>Lancet, The</i> , 2022, 399, 1379-1380.	6.3	1
1347	The Immunomodulatory Effects of Statins on Macrophages. <i>Immuno</i> , 2022, 2, 317-343.	0.6	11
1348	The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study. <i>Journal of Psychopharmacology</i> , 2021, 35, 1479-1487.	2.0	9
1349	Efficacy of using walnuts as statin adjuvants in hypertension management. <i>Clinical and Experimental Hypertension</i> , 2022, 44, 419-426.	0.5	1
1353	Preventing Recurrent Stroke and Other Serious Vascular Events. , 0, , 789-901.		4
1354	Treatment of Endothelial Dysfunction and Atherosclerosis by Cholesterol Lowering. , 0, , 300-314.		0
1356	Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. <i>BMJ, The</i> , 2022, 376, e067731.	3.0	14
1357	Statins are associated with a large reduction in all-cause mortality in women from a cardiac outpatient population. <i>Open Heart</i> , 2022, 9, e001900.	0.9	7
1358	Hip circumference is associated with high density lipoprotein cholesterol response following statin therapy in hypertensive subjects. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 680-4.	1.8	2

#	ARTICLE	IF	CITATIONS
1359	Undertreatment or Overtreatment With Statins: Where Are We?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 808712.	1.1	9
1360	Repurposing drugs to treat cardiovascular disease in the era of precision medicine. <i>Nature Reviews Cardiology</i> , 2022, 19, 751-764.	6.1	29
1361	Genetically predicted on-statin LDL response is associated with higher intracerebral haemorrhage risk. <i>Brain</i> , 2022, 145, 2677-2686.	3.7	15
1363	Increased BMI and Blood Lipids Are Associated With a Hypercoagulable State in the Moli-sani Cohort. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
1364	Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1842-1851.	0.8	7
1366	Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LiFestyle Cohort Twente (DIALECT). <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
1367	Lipid cutoffs for increased cardiovascular disease risk in non-diabetic young people. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1866-1877.	0.8	2
1368	â¼¼Inclisiran: more hope less hype. <i>Drug and Therapeutics Bulletin</i> , 2022, 60, 102-107.	0.3	5
1369	Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	12
1370	Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 119-129.	1.3	0
1371	Influence of intensive lipidâ€w lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study. <i>Clinical Cardiology</i> , 2022, 45, 986-994.	0.7	1
1372	Statin Myopathy. , 2022, , 137-147.		0
1373	Immune system-wide Mendelian randomization and triangulation analyses support autoimmunity as a modifiable component in dementia-causing diseases. <i>Nature Aging</i> , 2022, 2, 956-972.	5.3	11
1374	Low-density lipoprotein cholesterol goal attainment in patients with clinical evidence of familial hypercholesterolemia and elevated Lp(a). <i>Lipids in Health and Disease</i> , 2022, 21, .	1.2	3
1375	Therapeutic Response of Serum Lipids to Atorvastatin in Type II Diabetic Patients. <i>Iraqi Journal of Pharmaceutical Sciences</i> , 2022, 21, 21-26.	0.1	0
1376	Statins and neuroprotective effects. <i>Neurologie Pro Praxi</i> , 2021, 22, 45-49.	0.0	0
1377	Facts and ideas on statins with respect to their lipophilicity: a focus on skeletal muscle cells and bone besides known cardioprotection. <i>Molecular and Cellular Biochemistry</i> , 0, , .	1.4	1
1378	The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. , 2023, 2, 122-164.		1

#	ARTICLE	IF	CITATIONS
1379	Simvastatin for lowering lipids. The Cochrane Library, 2023, 2023, .	1.5	1
1380	The Effect of Plant-Based and Mycoprotein-Based Meat Substitute Consumption on Cardiometabolic Risk Factors: A Systematic Review and Meta-Analysis of Controlled Intervention Trials. <i>Dietetics</i> , 2023, 2, 104-122.	0.4	3
1381	Lovastatin for lowering lipids. The Cochrane Library, 2023, 2023, .	1.5	0
1382	High-Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population-Based Cohort Study. <i>Journal of the American Heart Association</i> , 2023, 12, .	1.6	0
1388	Treatment Guidelines Overview. , 2024, , 101-112.e1.		0
1404	The Role of Statins in ASCVD. , 0, , .		0
1405	14. Dyslipidemia. , 2023, , .		0